

**OBI PHARMA, INC. AND SUBSIDIARIES**  
**CONSOLIDATED FINANCIAL STATEMENTS AND**  
**INDEPENDENT AUDITORS' REPORT**  
**DECEMBER 31, 2025 AND 2024**

---

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

## INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of OBI PHARMA, INC.

***Opinion***

We have audited the accompanying parent company only balance sheets of OBI PHARMA, INC. (the "Company") as at December 31, 2025 and 2024, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

***Basis for opinion***

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

***Key audit matters***

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2025 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matter for the Company's 2025 parent company only financial statements is stated as follows:

***Key audit matter - Impairment assessment of investments accounted for using equity method*****Description**

Refer to Note 4(11) for accounting policies on investments accounted for using equity method—subsidiary, Note 5 for critical judgement adopted in the impairment assessment of investments accounted for using equity method, and Note 6(5) for details of investments accounted for using equity method in the parent company only financial statements.

The Company's investee, Amaran Biotechnology Inc. (Amaran), had significant amounts of property, plant and equipment and right-of-use assets. As of the balance sheet date, Amaran assesses whether there is any indication of impairment based on the external and internal information. If there is an indication that these assets may be impaired, these assets are tested for impairment based on their fair values or recoverable amounts. As the amount of investments accounted for using equity method is significant, the assessment of fair value and recoverable amount involves management's subjective judgement, and the key assumptions used in the impairment assessment have a significant impact on the impairment assessment result, we considered the impairment assessment of investments accounted for using equity method as a key audit matter.

#### How our audit addressed the matter

We performed the following audit procedures on the above key audit matter:

1. Reviewed and assessed the reasonableness of the data used in the assessment of impairment indication of property, plant and equipment and right-of-use assets.
2. Obtained an understanding of the reasonableness of future cash flows forecast developed by management of subsidiary.
3. Discussed financial operation forecast with management of subsidiary, and compared the forecast with historical results for reasonableness.
4. Reviewed the reasonableness of other significant assumptions used by management of subsidiary in determining future cash flows.
5. Reviewed and assessed the estimated fair value of its property, plant, and equipment.

#### ***Responsibilities of management and those charged with governance for the parent company only financial statements***

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

***Auditors' responsibilities for the audit of the parent company only financial statements***

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of

accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

---

Teng, Sheng-Wei

---

Liang, Hua-Ling

For and on Behalf of PricewaterhouseCoopers, Taiwan

March 9, 2026

---

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

**OBI PHARMA, INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
**DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

| Assets                    | Notes   | December 31, 2025 |                     | December 31, 2024 |                     |            |
|---------------------------|---|-------------------|---------------------|-------------------|---------------------|------------|
|                           |   | AMOUNT            | %                   | AMOUNT            | %                   |            |
| <b>Current assets</b>     |   |                   |                     |                   |                     |            |
| 1100                      | Cash and cash equivalents   | 6(1)              | \$ 759,330          | 22                | \$ 1,732,050        | 31         |
| 1110                      | Current financial assets at fair value through profit or loss                   | 6(2)              | -                   | -                 | 89                  | -          |
| 1136                      | Current financial assets at amortised cost                                      | 6(4)              | 427,000             | 12                | 1,398,700           | 25         |
| 1140                      | Current contract assets   | 6(19)             | 2,414               | -                 | -                   | -          |
| 1170                      | Accounts receivable, net  |                   | 10,298              | -                 | 4,200               | -          |
| 1200                      | Other receivables   |                   | 54,150              | 2                 | 19,005              | -          |
| 130X                      | Inventories   |                   | 18,430              | 1                 | 27,725              | -          |
| 1410                      | Prepayments   | 6(5)              | 308,463             | 9                 | 258,014             | 5          |
| 11XX                      | <b>Total current assets</b>   |                   | <u>1,580,085</u>    | <u>46</u>         | <u>3,439,783</u>    | <u>61</u>  |
| <b>Non-current assets</b> |   |                   |                     |                   |                     |            |
| 1517                      | Financial assets at fair value through other comprehensive income - non-current | 6(3)              | 7,455               | -                 | 9,017               | -          |
| 1535                      | Financial assets at amortised cost - non-current                                | 6(4) and 8        | 16,400              | 1                 | 12,900              | -          |
| 1550                      | Investments accounted for using equity method                                   | 6(6)              | 739,886             | 22                | 937,933             | 17         |
| 1600                      | Property, plant and equipment   | 6(7) and 8        | 665,476             | 19                | 778,643             | 14         |
| 1755                      | Right-of-use assets   | 6(8)              | 328,818             | 10                | 386,442             | 7          |
| 1780                      | Intangible assets   | 6(9)              | 46,860              | 1                 | 62,840              | 1          |
| 1900                      | Other non-current assets  | 8                 | 36,285              | 1                 | 26,134              | -          |
| 15XX                      | <b>Total non-current assets</b>   |                   | <u>1,841,180</u>    | <u>54</u>         | <u>2,213,909</u>    | <u>39</u>  |
| 1XXX                      | <b>Total assets</b>   |                   | <u>\$ 3,421,265</u> | <u>100</u>        | <u>\$ 5,653,692</u> | <u>100</u> |

(Continued)

**OBI PHARMA, INC. AND SUBSIDIARIES**  
**CONSOLIDATED BALANCE SHEETS**  
**DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars)

| Liabilities and Equity   |  | Notes          | December 31, 2025   |            | December 31, 2024   |            |
|--|--|----------------|---------------------|------------|---------------------|------------|
|  |  |                | AMOUNT              | %          | AMOUNT              | %          |
| <b>Current liabilities</b>   |  |                |                     |            |                     |            |
| 2100   | Current borrowings                                 | 6(10) and 8    | \$ 50,353           | 2          | \$ 412              | -          |
| 2130   | Current contract liabilities                       | 6(19)          | 2,293               | -          | 7,783               | -          |
| 2150   | Notes payable                                      |                | -                   | -          | 540                 | -          |
| 2170   | Accounts payable                                   |                | 985                 | -          | 2,900               | -          |
| 2200   | Other payables                                     | 6(12)          | 116,870             | 3          | 297,833             | 5          |
| 2230   | Current income tax liabilities                     |                | 2,455               | -          | 10,394              | -          |
| 2250   | Current provisions                                 | 6(13)          | 49,286              | 1          | -                   | -          |
| 2280   | Current lease liabilities                          |                | 54,017              | 2          | 55,116              | 1          |
| 2320   | Long-term liabilities, current portion             | 6(11) and 8    | 71,870              | 2          | 34,091              | 1          |
| 2399   | Other current liabilities                          |                | 2,428               | -          | 3,301               | -          |
| 21XX   | <b>Total current liabilities</b>                   |                | <u>350,557</u>      | <u>10</u>  | <u>412,370</u>      | <u>7</u>   |
| <b>Non-current liabilities</b>   |  |                |                     |            |                     |            |
| 2540   | Long-term borrowings                               | 6(11) and 8    | 29,458              | 1          | 48,220              | 1          |
| 2550   | Non-current provisions                             | 6(13)          | 6,137               | -          | 6,008               | -          |
| 2580   | Non-current lease liabilities                      |                | 309,979             | 9          | 366,787             | 7          |
| 25XX   | <b>Total non-current liabilities</b>               |                | <u>345,574</u>      | <u>10</u>  | <u>421,015</u>      | <u>8</u>   |
| 2XXX   | <b>Total liabilities</b>                           |                | <u>696,131</u>      | <u>20</u>  | <u>833,385</u>      | <u>15</u>  |
| <b>Equity</b>  |  |                |                     |            |                     |            |
| <b>Equity attributable to owners of parent</b>                           |  |                |                     |            |                     |            |
| Share capital  |  |                |                     |            |                     |            |
| 3110   | Common stock                                       | 6(16)          | 1,315,797           | 39         | 2,631,594           | 46         |
| Capital surplus  |  |                |                     |            |                     |            |
| 3200   | Capital surplus                                    | 6(15)(17)(28)  | 9,204,370           | 269        | 9,100,741           | 161        |
| Retained earnings  |  |                |                     |            |                     |            |
| 3350   | Accumulated deficit                                | 6(18)          | ( 8,616,065)        | ( 252)     | ( 7,879,039)        | ( 139)     |
| 3400   | Other equity interest                              |                | ( 15,546)           | ( 1)       | ( 12,089)           | -          |
| 3500   | Treasury shares                                    | 6(16)(17)(28)  | -                   | -          | ( 26,533)           | ( 1)       |
| 31XX   | <b>Equity attributable to owners of the parent</b> |                | <u>1,888,556</u>    | <u>55</u>  | <u>3,814,674</u>    | <u>67</u>  |
| 36XX   | Non-controlling interest                           | 4(3) and 6(28) | <u>836,578</u>      | <u>25</u>  | <u>1,005,633</u>    | <u>18</u>  |
| 3XXX   | <b>Total equity</b>                                |                | <u>2,725,134</u>    | <u>80</u>  | <u>4,820,307</u>    | <u>85</u>  |
| Significant Contingent Liabilities and Unrecognised Contract Commitments |  |                |                     |            |                     |            |
| Significant Events after the Balance Sheet Date                          |  |                |                     |            |                     |            |
| 3X2X   | <b>Total liabilities and equity</b>                |                | <u>\$ 3,421,265</u> | <u>100</u> | <u>\$ 5,653,692</u> | <u>100</u> |

The accompanying notes are an integral part of these consolidated financial statements.

**OBI PHARMA, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**YEARS ENDED DECEMBER 31, 2025 AND 2024**  
(Expressed in thousands of New Taiwan dollars, except for loss per share amounts)

|      | Items   | Notes                                | Year ended December 31 |               |                       |               |
|------|---|--------------------------------------|------------------------|---------------|-----------------------|---------------|
|      |   |                                      | 2025                   |               | 2024                  |               |
|      |   |                                      | AMOUNT                 | %             | AMOUNT                | %             |
| 4000 | Operating revenue   | 6(19) and 7                          | \$ 58,575              | 3             | \$ 62,678             | 3             |
| 5000 | Operating costs   |                                      | ( 136,104)             | ( 6)          | ( 138,952)            | ( 6)          |
| 5900 | Gross loss  |                                      | ( 77,529)              | ( 3)          | ( 76,274)             | ( 3)          |
|      | Operating expenses  | 6(7)(8)(9)(14)(15)<br>(24)(25) and 7 |                        |               |                       |               |
| 6200 | Administrative expenses   |                                      | ( 361,964)             | ( 16)         | ( 326,777)            | ( 13)         |
| 6300 | Research and development expenses   |                                      | ( 1,729,293)           | ( 77)         | ( 1,968,477)          | ( 79)         |
| 6000 | Total operating expenses  |                                      | ( 2,091,257)           | ( 93)         | ( 2,295,254)          | ( 92)         |
| 6900 | Operating loss  |                                      | ( 2,168,786)           | ( 96)         | ( 2,371,528)          | ( 95)         |
|      | Non-operating income and expenses   |                                      |                        |               |                       |               |
| 7100 | Interest income   | 6(20)                                | 29,794                 | 1             | 40,071                | 2             |
| 7010 | Other income  | 6(21) and 7                          | 47,993                 | 2             | 13,120                | -             |
| 7020 | Other gains and losses  | 6(22)                                | 46,645                 | 2             | 65,957                | 3             |
| 7050 | Finance costs   | 6(23)                                | ( 13,133)              | -             | ( 10,651)             | ( 1)          |
| 7060 | Share of loss of associates and joint ventures accounted for using equity method  | 6(6)                                 | ( 201,993)             | ( 9)          | ( 233,177)            | ( 9)          |
| 7000 | Total non-operating income and expenses   |                                      | ( 90,694)              | ( 4)          | ( 124,680)            | ( 5)          |
| 7900 | <b>Loss before tax</b>  |                                      | ( 2,259,480)           | ( 100)        | ( 2,496,208)          | ( 100)        |
| 7950 | Income tax benefit  | 6(26)                                | 2,726                  | -             | 3,562                 | -             |
| 8200 | <b>Loss for the year</b>  |                                      | <u>(\$ 2,256,754)</u>  | <u>( 100)</u> | <u>(\$ 2,492,646)</u> | <u>( 100)</u> |
|      | <b>Other comprehensive income (loss) Components of other comprehensive income (loss) that will not be reclassified to profit or loss</b>  |                                      |                        |               |                       |               |
| 8316 | Unrealised valuation gain or loss from equity investment instruments measured at fair value through other comprehensive income  | 6(3)                                 | (\$ 1,562)             | -             | (\$ 1,604)            | -             |
|      | <b>Components of other comprehensive income (loss) that will be reclassified to profit or loss</b>  |                                      |                        |               |                       |               |
| 8361 | Financial statements translation differences of foreign operations  |                                      | ( 3,148)               | -             | 4,666                 | -             |
| 8370 | Share of other comprehensive income (loss) of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss |                                      | 565                    | -             | ( 259)                | -             |
| 8300 | <b>Other comprehensive (loss) income for the year, net</b>  |                                      | <u>(\$ 4,145)</u>      | <u>-</u>      | <u>\$ 2,803</u>       | <u>-</u>      |
| 8500 | <b>Total comprehensive loss for the year</b>  |                                      | <u>(\$ 2,260,899)</u>  | <u>( 100)</u> | <u>(\$ 2,489,843)</u> | <u>( 100)</u> |
|      | Loss attributable to:   |                                      |                        |               |                       |               |
| 8610 | Owners of the parent  |                                      | (\$ 2,052,823)         | ( 91)         | (\$ 2,310,026)        | ( 93)         |
| 8620 | Non-controlling interest  |                                      | ( 203,931)             | ( 9)          | ( 182,620)            | ( 7)          |
|      | Total   |                                      | <u>(\$ 2,256,754)</u>  | <u>( 100)</u> | <u>(\$ 2,492,646)</u> | <u>( 100)</u> |
|      | Comprehensive loss attributable to:   |                                      |                        |               |                       |               |
| 8710 | Owners of the parent  |                                      | (\$ 2,056,968)         | ( 91)         | (\$ 2,306,502)        | ( 93)         |
| 8720 | Non-controlling interest  |                                      | ( 203,931)             | ( 9)          | ( 183,341)            | ( 7)          |
|      | Total   |                                      | <u>(\$ 2,260,899)</u>  | <u>( 100)</u> | <u>(\$ 2,489,843)</u> | <u>( 100)</u> |
|      | Loss per share (in dollars)   | 6(27)                                |                        |               |                       |               |
| 9750 | Basic and diluted loss per share  |                                      | <u>(\$ 15.61)</u>      |               | <u>(\$ 19.78)</u>     |               |

The accompanying notes are an integral part of these consolidated financial statements.

OBI PHARMA, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

|   | Notes             | Equity attributable to owners of the parent |                            |                     |  |  |                      |                 |               | Non-controlling interest | Total equity  |
|---|-------------------|---|----------------------------|---------------------|--|--|----------------------|-----------------|---------------|--------------------------|---------------|
|   |                   | Share capital - common stock                | Additional paid-in capital | Accumulated deficit | Financial statements translation differences of foreign operations | Other equity interest<br>Unrealised losses from financial assets measured at fair value through other comprehensive income | Other equity, others | Treasury stocks | Total         |                          |               |
| <b>Year ended December 31, 2024</b>   |                   |   |                            |                     |  |  |                      |                 |               |                          |               |
| Balance at January 1, 2024  |                   | \$ 2,294,394                                | \$ 7,127,750               | (\$ 5,569,013)      | \$ 2,300   | (\$ 16,560)  | (\$ 5,607)           | (\$ 26,533)     | \$ 3,806,731  | \$ 1,146,711             | \$ 4,953,442  |
| Net loss for the year   |                   | -   | -                          | ( 2,310,026 )       | -  | -  | -                    | -               | ( 2,310,026 ) | ( 182,620 )              | ( 2,492,646 ) |
| Other comprehensive income (loss) for the year  |                   | -   | -                          | -                   | 5,128  | ( 1,604 )  | -                    | -               | 3,524         | ( 721 )                  | 2,803         |
| Total comprehensive income (loss) for the year  |                   | -   | -                          | ( 2,310,026 )       | 5,128  | ( 1,604 )  | -                    | -               | ( 2,306,502 ) | ( 183,341 )              | ( 2,489,843 ) |
| Issuance of shares  |                   | 338,000                                     | 1,825,200                  | -                   | -  | -  | -                    | -               | 2,163,200     | -                        | 2,163,200     |
| Share-based payment transactions  | 6(15)(17)(25)(28) | -   | 36,635                     | -                   | -  | -  | -                    | -               | 36,635        | 27,736                   | 64,371        |
| Compensation cost of employee restricted stocks   | 6(15)(25)         | -   | -                          | -                   | -  | -  | 3,415                | -               | 3,415         | -                        | 3,415         |
| Cancellation of employee restricted stocks  | 6(15)(25)         | ( 800 )                                     | ( 4,480 )                  | -                   | -  | -  | 1,236                | -               | ( 4,044 )     | -                        | ( 4,044 )     |
| Forfeiture of share options   | 6(15)(17)(28)     | -   | 3,681                      | -                   | -  | -  | -                    | -               | 3,681         | ( 3,681 )                | -             |
| Changes in equity of associates accounted for using equity method                         |                   | -   | 111,955                    | -                   | -  | -  | -                    | -               | 111,955       | -                        | 111,955       |
| Disposal of subsidiaries  | 4(3)              | -   | -                          | -                   | ( 397 )  | -  | -                    | -               | ( 397 )       | 18,208                   | 17,811        |
| Balance at December 31, 2024  |                   | \$ 2,631,594                                | \$ 9,100,741               | (\$ 7,879,039)      | \$ 7,031   | (\$ 18,164)  | (\$ 956)             | (\$ 26,533)     | \$ 3,814,674  | \$ 1,005,633             | \$ 4,820,307  |
| <b>Year ended December 31, 2025</b>   |                   |   |                            |                     |  |  |                      |                 |               |                          |               |
| Balance at January 1, 2025  |                   | \$ 2,631,594                                | \$ 9,100,741               | (\$ 7,879,039)      | \$ 7,031   | (\$ 18,164)  | (\$ 956)             | (\$ 26,533)     | \$ 3,814,674  | \$ 1,005,633             | \$ 4,820,307  |
| Net loss for the year   |                   | -   | -                          | ( 2,052,823 )       | -  | -  | -                    | -               | ( 2,052,823 ) | ( 203,931 )              | ( 2,256,754 ) |
| Other comprehensive loss for the year   |                   | -   | -                          | -                   | ( 2,583 )  | ( 1,562 )  | -                    | -               | ( 4,145 )     | -                        | ( 4,145 )     |
| Total comprehensive loss for the year   |                   | -   | -                          | ( 2,052,823 )       | ( 2,583 )  | ( 1,562 )  | -                    | -               | ( 2,056,968 ) | ( 203,931 )              | ( 2,260,899 ) |
| Capital reduction to cover accumulated deficit  |                   | ( 1,315,797 )                               | -                          | 1,315,797           | -  | -  | -                    | -               | -             | -                        | -             |
| Share-based payment transactions  | 6(15)(17)(25)(28) | -   | 13,372                     | -                   | -  | -  | -                    | -               | 13,372        | 17,686                   | 31,058        |
| Compensation cost of employee restricted stocks   | 6(15)(25)         | -   | -                          | -                   | -  | -  | 688                  | -               | 688           | -                        | 688           |
| Subsidiary employees exercising stock options   | 6(15)(17)(28)     | -   | 267                        | -                   | -  | -  | -                    | -               | 267           | 19,583                   | 19,850        |
| Subsidiary capital collected in advance   | 6(28)             | -   | -                          | -                   | -  | -  | -                    | -               | -             | 1,055                    | 1,055         |
| Forfeiture of share options   | 6(15)(17)(28)     | -   | 8,539                      | -                   | -  | -  | -                    | -               | 8,539         | ( 8,539 )                | -             |
| Changes in equity of associates accounted for using equity method                         |                   | -   | 3,380                      | -                   | -  | -  | -                    | -               | 3,380         | -                        | 3,380         |
| Difference between consideration and carrying amount of subsidiaries acquired or disposed | 6(17)(28)         | -   | 99,683                     | -                   | -  | -  | -                    | -               | 99,683        | 3,058                    | 102,741       |
| Subsidiary disposal of parent company shares  | 6(16)(17)(28)     | -   | ( 21,612 )                 | -                   | -  | -  | -                    | 26,533          | 4,921         | 2,033                    | 6,954         |
| Balance at December 31, 2025  |                   | \$ 1,315,797                                | \$ 9,204,370               | (\$ 8,616,065)      | \$ 4,448   | (\$ 19,726)  | (\$ 268)             | \$ -            | \$ 1,888,556  | \$ 836,578               | \$ 2,725,134  |

The accompanying notes are an integral part of these consolidated financial statements.

OBI PHARMA, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

|   | Notes       | Year ended December 31 |                  |
|---|-------------|------------------------|------------------|
|   |             | 2025                   | 2024             |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>   |             |                        |                  |
| Loss before tax   |             | ( \$ 2,259,480 )       | ( \$ 2,496,208 ) |
| Adjustments   |             |                        |                  |
| Adjustments to reconcile profit (loss)  |             |                        |                  |
| Depreciation  | 6(7)(8)(24) | 206,783                | 203,403          |
| Amortisation  | 6(9)(24)    | 20,379                 | 18,851           |
| Interest expense  | 6(23)       | 13,133                 | 10,651           |
| Loss on financial assets at fair value through profit or loss                         | 6(2)(22)    | 89                     | 138              |
| Interest income   | 6(20)       | ( 29,794 )             | ( 40,071 )       |
| Losses (gains) on disposal of property, plant and equipment                           | 6(22)       | 122                    | ( 43,720 )       |
| Gain on disposal of intangible assets   | 6(22)       | ( 45,000 )             | -                |
| Compensation cost for share-based payment transactions                                | 6(15)       | 31,747                 | 63,976           |
| Share of loss of associates accounted for using equity method                         | 6(6)        | 201,993                | 233,177          |
| Gain on disposal of investments   | 6(22)       | -                      | ( 397 )          |
| Losses on lease modification  | 6(22)       | 3,001                  | -                |
| Property, plant and equipment transferred to expenses                                 |             | -                      | 399              |
| Changes in operating assets and liabilities   |             |                        |                  |
| Changes in operating assets   |             |                        |                  |
| Current contract assets   |             | ( 2,414 )              | -                |
| Accounts receivable, net  |             | ( 6,098 )              | 2,277            |
| Other receivables   |             | 5,200                  | 7,991            |
| Inventories   |             | 9,295                  | ( 1,793 )        |
| Prepayments   |             | ( 50,449 )             | ( 38,406 )       |
| Changes in operating liabilities  |             |                        |                  |
| Current contract liabilities  |             | ( 5,490 )              | 1,498            |
| Notes payable   |             | ( 540 )                | 540              |
| Accounts payable  |             | ( 1,915 )              | 2,127            |
| Other payables  |             | ( 175,342 )            | 200,856          |
| Other payables to related parties   |             | -                      | ( 16 )           |
| Current provisions  |             | 49,286                 | -                |
| Other current liabilities   |             | ( 873 )                | 48               |
| Cash outflow generated from operations  |             | ( 2,036,367 )          | ( 1,874,679 )    |
| Interest received   |             | 31,406                 | 43,440           |
| Interest paid   |             | ( 13,003 )             | ( 14,650 )       |
| Income tax (paid) received  |             | ( 2,170 )              | 12,376           |
| Net cash flows used in operating activities   |             | ( 2,020,134 )          | ( 1,833,513 )    |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>   |             |                        |                  |
| Acquisition of financial assets at amortised cost                                     |             | ( 793,100 )            | ( 1,638,800 )    |
| Proceeds from disposal of financial assets at amortised cost                          |             | 1,761,300              | 2,119,928        |
| Decrease in cash from disposal of subsidiaries  | 6(29)       | -                      | ( 30,414 )       |
| Acquisition of property, plant and equipment  | 6(29)       | ( 42,961 )             | ( 111,221 )      |
| Proceeds from disposal of property, plant and equipment                               |             | 260                    | 144,632          |
| Acquisition of intangible assets  | 6(9)        | ( 4,399 )              | ( 6,321 )        |
| Increase in prepayments for business facilities (shown as 'other non-current assets') |             | ( 912 )                | ( 2,015 )        |
| (Increase) decrease in refundable deposits (shown as 'other non-current assets')      |             | ( 11,254 )             | 7,229            |
| Net cash flows from investing activities  |             | 908,934                | 483,018          |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>   |             |                        |                  |
| Repayment of lease principal  | 6(8)(30)    | ( 57,927 )             | ( 45,746 )       |
| Increase in short-term borrowings   |             | 114,353                | 412              |
| Repayment of short-term borrowings  |             | ( 64,412 )             | ( 4,305 )        |
| Increase in long-term debt  |             | 75,000                 | 100,000          |
| Repayment of long-term debt   |             | ( 55,983 )             | ( 38,689 )       |
| Decrease in guarantee deposits received   | 6(30)       | -                      | ( 3 )            |
| Proceeds from cash capital increase   | 6(16)       | -                      | 2,163,200        |
| Subsidiary employees exercising stock options   | 6(28)       | 19,850                 | -                |
| Subsidiary capital collected in advance   | 6(28)       | 1,055                  | -                |
| Disposal of the shares of parent company held by the subsidiary                       | 6(28)       | 6,954                  | -                |
| Disposal of ownership interests in subsidiaries (without losing control)              | 6(28)       | 102,741                | -                |
| Net cash flows from financing activities  |             | 141,631                | 2,174,869        |

(Continued)

OBI PHARMA, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED DECEMBER 31, 2025 AND 2024  
(Expressed in thousands of New Taiwan dollars)

|  | Notes | Year ended December 31 |                     |
|--|-------|------------------------|---------------------|
|  |       | 2025                   | 2024                |
| Effect due to changes in exchange rate               |       | ( \$ 3,151 )           | \$ 8,399            |
| Net (decrease) increase in cash and cash equivalents |       | ( 972,720 )            | 832,773             |
| Cash and cash equivalents at beginning of year       |       | 1,732,050              | 899,277             |
| Cash and cash equivalents at end of year             |       | <u>\$ 759,330</u>      | <u>\$ 1,732,050</u> |

The accompanying notes are an integral part of these consolidated financial statements.

OBI PHARMA, INC. AND SUBSIDIARIES  
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS  
YEARS ENDED DECEMBER 31, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

OBI PHARMA, INC. (the “Company”) was established on April 29, 2002 upon approval by the Ministry of Economic Affairs. The Company conducted the initial public offering in May 2012, and traded its shares on the Emerging Stock Market of the Taipei Exchange (formerly GreTai Securities Market) since March 23, 2015. The Company and its subsidiaries (collectively referred herein as the “Group”) are primarily engaged in new drugs research.

2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on March 9, 2026.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS<sup>®</sup>”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

| New Standards, Interpretations and Amendments   | Effective date by<br>International Accounting<br>Standards Board |
|---|--|
| Amendments to IAS 21, ‘Lack of exchangeability’ | January 1, 2025  |

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

| New Standards, Interpretations and Amendments  | Effective date by<br>International Accounting<br>Standards Board |
|--|--|
| Amendments to IFRS 9 and IFRS 7, ‘Amendments to the classification and measurement of financial instruments’ | January 1, 2026  |
| Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-dependent electricity’                        | January 1, 2026  |
| IFRS 17, ‘Insurance contracts’   | January 1, 2023  |
| Amendments to IFRS 17, ‘Insurance contracts’   | January 1, 2023  |
| Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 – comparative information’                  | January 1, 2023  |
| Annual Improvements to IFRS Accounting Standards—Volume 11   | January 1, 2026  |

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

| New Standards, Interpretations and Amendments   | Effective date by<br>International Accounting<br>Standards Board   |
|---|--|
| Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’ | To be determined by<br>International Accounting<br>Standards Board |
| IFRS 18, ‘Presentation and disclosure in financial statements’  | January 1, 2027 (Note)   |
| IFRS 19, ‘Subsidiaries without public accountability: disclosures’  | January 1, 2027  |
| Amendments to IAS 21, ‘Translation to a Hyperinflationary Presentation Currency’  | January 1, 2027  |

Note : The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces a defined structure of the statement of profit or loss, disclosure requirements related to management-defined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

#### 4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

##### (1) Compliance statement

The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, International Financial Reporting Standards, International Accounting Standards, IFRIC<sup>®</sup> Interpretations, and SIC<sup>®</sup> Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”).

##### (2) Basis of preparation

- A. Except for the financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income, these consolidated financial statements have been prepared under the historical cost convention.
- B. The preparation of financial statements in conformity with IFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

##### (3) Basis of consolidation

- A. Basis for preparation of consolidated financial statements:
  - (a) All subsidiaries are included in the Group’s consolidated financial statements. Subsidiaries are all entities (including structured entities) controlled by the Group. The Group controls an entity when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. Consolidation of subsidiaries begins from the date the Group obtains control of the subsidiaries and ceases when the Group loses control of the subsidiaries.
  - (b) Inter-company transactions, balances and unrealised gains or losses on transactions between companies within the Group are eliminated. Accounting policies of subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Group.
  - (c) When the Group loses control of a subsidiary, the Group remeasures any investment retained in the former subsidiary at its fair value. That fair value is regarded as the fair value on initial recognition of a financial asset or the cost on initial recognition of the associate or joint venture. Any difference between fair value and book value is recognised in profit or loss. All amounts previously recognised in other comprehensive income in relation to the subsidiary are reclassified to profit or loss on the same basis as would be required if the related assets or liabilities were disposed of. That is, when the Group loses control of a subsidiary, all gains or

losses previously recognised in other comprehensive income in relation to the subsidiary should be reclassified from equity to profit or loss, if such gains or losses would be reclassified to profit or loss when the related assets or liabilities are disposed of.

(d) Shares of the Company held by subsidiaries are treated as treasury shares.

B. Subsidiaries included in the consolidated financial statements and movements for the year are as follows:

| Name of investor                       | Name of subsidiary                     | Main business activities  | Ownership (%)     |                   | Description |
|--|--|---|-------------------|-------------------|-------------|
|  |  |   | December 31, 2025 | December 31, 2024 |             |
| The Company                            | OBI Pharma Limited                     | Investing and trading   | -                 | -                 | Note 1      |
| The Company                            | OBI Pharma USA, Inc.                   | Biotechnology development   | 100.00            | 100.00            |             |
| The Company                            | OBI Pharma Australia Pty Ltd.          | Biotechnology development   | 100.00            | 100.00            |             |
| The Company                            | Odeon Therapeutics (Cayman) Limited    | Investing and trading   | -                 | -                 | Note 2      |
| The Company                            | Amaran Biotechnology Inc.              | Manufacture and wholesale of western pharmaceuticals as well as research and development of biotechnology | 70.68             | 70.70             |             |
| The Company                            | Obigen Pharma, Inc.                    | Biotechnology development   | 49.57             | 51.94             | Note 3      |
| Odeon Therapeutics (Cayman) Limited    | Odeon Therapeutics (Hong Kong) Limited | Investing and trading   | -                 | -                 | Note 2      |
| Odeon Therapeutics (Hong Kong) Limited | Odeon (Shanghai) Therapeutics Co. Ltd. | Biotechnology development   | -                 | -                 | Note 2      |

Note 1 : On May 8, 2023, the Board of Directors of the Company resolved to liquidate OBI Pharma Limited, and the liquidation procedures were completed in March 2024.

Note 2 : On May 10, 2024, the Board of Directors of the Company resolved to terminate the exclusive licensing agreement in China (including Hong Kong and Macao) of OBI-833 (Globo H Adagloxad Simolenin) and OBI-999 (Globo H Antibody Drug Conjugate) entered into by the Company and Odeon Therapeutics (Hong Kong) Limited on February 22, 2022. Additionally, the Company signed a contract with Odeon Therapeutics (Hong Kong) Limited on the same day. The primary terms stated that any licenses and other rights granted by the Company to Odeon Therapeutics (Hong Kong) in the past will terminate and revert to the Company and the 6,000 thousand preferred shares of Odeon Therapeutics (Cayman) Limited (hereafter referred to as "Odeon") held by the Company

shall be returned according to the agreement. Consequently, the Company lost its control over Odeon and its subsidiaries.

Note 3 : Although the Group's shareholding in Obigen Pharma, Inc. is less than 50%, the Group holds majority voting rights in its shareholders' meetings and has decision-making rights over its financial, operational, and personnel matters. The Group therefore directs its relevant activities and has control over it.

- C. Subsidiaries not included in the consolidated financial statements: None.
- D. Adjustments for subsidiaries with different balance sheet dates: None.
- E. Significant restrictions: None.
- F. Subsidiaries that have non-controlling interests that are material to the Group:

As of December 31, 2025 and 2024, the non-controlling interest amounted to \$836,578 and \$1,005,633, respectively. The information on non-controlling interest and respective subsidiaries is as follows:

| Name of subsidiary        | Principal place of business | Non-controlling interest |           |                   |           | Description |
|---------------------------|-----------------------------|--------------------------|-----------|-------------------|-----------|-------------|
|                           |                             | December 31, 2025        |           | December 31, 2024 |           |             |
|                           |                             | Amount                   | Ownership | Amount            | Ownership |             |
| Amaran Biotechnology Inc. | Taiwan                      | \$ 124,824               | 29.32%    | \$ 171,832        | 29.30%    | Note        |
| Obigen Pharma, Inc.       | Taiwan                      | 711,754                  | 50.43%    | 833,801           | 48.06%    |             |

Note: Shares of the Company held by subsidiaries are treated as treasury shares. Thus, the non-controlling interest as of December 31, 2025 and 2024 decreased by \$0 and \$10,997, respectively.

Summarised financial information of the subsidiaries:

Balance sheets

|                         | Amaran Biotechnology Inc. |                   |
|-------------------------|---------------------------|-------------------|
|                         | December 31, 2025         | December 31, 2024 |
| Current assets          | \$ 83,623                 | \$ 107,907        |
| Non-current assets      | 501,797                   | 542,149           |
| Current liabilities     | ( 175,708)                | ( 76,880)         |
| Non-current liabilities | ( 104,122)                | ( 124,985)        |
| Total net assets        | \$ 305,590                | \$ 448,191        |

|                         | Obigen Pharma, Inc. |                     |
|-------------------------|---------------------|---------------------|
|                         | December 31, 2025   | December 31, 2024   |
| Current assets          | \$ 637,289          | \$ 837,865          |
| Non-current assets      | 846,849             | 956,309             |
| Current liabilities     | ( 34,828)           | ( 37,369)           |
| Non-current liabilities | ( 66,627)           | ( 81,711)           |
| Total net assets        | <u>\$ 1,382,683</u> | <u>\$ 1,675,094</u> |

Statements of comprehensive income

|   | Amaran Biotechnology Inc. |                     |
|---|---------------------------|---------------------|
|   | Years ended December 31,  |                     |
|   | 2025                      | 2024                |
| Revenue   | \$ 69,275                 | \$ 87,407           |
| Loss before tax   | ( 163,501)                | ( 148,488)          |
| Income tax benefit  | -                         | -                   |
| Loss for the year   | ( 163,501)                | ( 148,488)          |
| Other comprehensive loss                                    | -                         | -                   |
| Total comprehensive loss for the year                       | <u>(\$ 163,501)</u>       | <u>(\$ 148,488)</u> |
| Comprehensive loss attributable to non-controlling interest | <u>(\$ 45,340)</u>        | <u>(\$ 42,649)</u>  |

|   | Obigen Pharma, Inc.      |                     |
|---|--------------------------|---------------------|
|   | Years ended December 31, |                     |
|   | 2025                     | 2024                |
| Revenue   | \$ -                     | \$ -                |
| Loss before tax   | ( 325,963)               | ( 274,308)          |
| Income tax benefit  | -                        | -                   |
| Loss for the year   | ( 325,963)               | ( 274,308)          |
| Other comprehensive loss                                    | -                        | -                   |
| Total comprehensive loss for the year                       | <u>(\$ 325,963)</u>      | <u>(\$ 274,308)</u> |
| Comprehensive loss attributable to non-controlling interest | <u>(\$ 158,591)</u>      | <u>(\$ 131,821)</u> |

## Statements of cash flows

|  | Amaran Biotechnology Inc. |                  |
|--|---------------------------|------------------|
|  | Years ended December 31,  |                  |
|  | 2025                      | 2024             |
| Net cash used in operating activities                | (\$ 98,353)               | (\$ 51,454)      |
| Net cash used in investing activities                | ( 19,913)                 | ( 11,112)        |
| Net cash provided by financing activities            | 97,263                    | 76,153           |
| Net (decrease) increase in cash and cash equivalents | ( 21,003)                 | 13,587           |
| Cash and cash equivalents at beginning of year       | 67,843                    | 54,256           |
| Cash and cash equivalents at end of year             | <u>\$ 46,840</u>          | <u>\$ 67,843</u> |

|   | Obigen Pharma, Inc.      |                   |
|---|--------------------------|-------------------|
|   | Years ended December 31, |                   |
|   | 2025                     | 2024              |
| Net cash used in operating activities               | (\$ 243,261)             | (\$ 142,131)      |
| Net cash provided by investing activities           | 176,023                  | 99,461            |
| Net cash provided by (used in) financing activities | 5,747                    | ( 13,012)         |
| Net decrease in cash and cash equivalents           | ( 61,491)                | ( 55,682)         |
| Cash and cash equivalents at beginning of year      | 148,862                  | 204,544           |
| Cash and cash equivalents at end of year            | <u>\$ 87,371</u>         | <u>\$ 148,862</u> |

### (4) Foreign currency translation

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). The consolidated financial statements are presented in New Taiwan dollars, which is the Company's functional and the Group's presentation currency.

#### A. Foreign currency transactions and balances

- (a) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.
- (b) Monetary assets and liabilities denominated in foreign currencies at the period end are retranslated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.
- (c) Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive

income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in other comprehensive income. However, nonmonetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.

- (d) All other foreign exchange gains and losses based on the nature of those transactions are presented in the statement of comprehensive income within “other gains and losses”.

#### B. Translation of foreign operations

The operating results and financial position of all the group entities that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- (a) Assets and liabilities for each balance sheet presented are translated at the closing exchange rate at the date of that balance sheet;
- (b) Income and expenses for each statement of comprehensive income are translated at average exchange rates of that period; and
- (c) All resulting exchange differences are recognised in other comprehensive income.

#### (5) Classification of current and non-current items

##### A. Assets that meet one of the following criteria are classified as current assets:

- (a) Assets arising from operating activities that are expected to be realised, or are intended to be sold or consumed within the normal operating cycle;
- (b) Assets held mainly for trading purposes;
- (c) Assets that are expected to be realised within twelve months from the balance sheet date;
- (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities more than twelve months after the balance sheet date.

Otherwise, they are classified as non-current assets.

##### B. Liabilities that meet one of the following criteria are classified as current liabilities:

- (a) Liabilities that are expected to be settled in the normal operating cycle;
- (b) Liabilities arising mainly from trading activities;
- (c) Liabilities that are to be settled within twelve months from the balance sheet date;
- (d) It does not have the right at the end of the reporting period to defer settlement of the liability at least twelve months after the reporting period.

Otherwise, they are classified as non-current liabilities.

#### (6) Cash equivalents

Cash equivalents refer to short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Time deposits that meet the definition above and are held for the purpose of meeting short-term cash commitments in

operations are classified as cash equivalents.

(7) Financial assets at fair value through profit or loss

- A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortised cost or fair value through other comprehensive income. Financial assets at amortised cost or fair value through other comprehensive income are designated as at fair value through profit or loss at initial recognition when they eliminate or significantly reduce a measurement or recognition inconsistency.
- B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value and recognises the transaction costs in profit or loss. The Group subsequently measures the financial assets at fair value, and recognises the gain or loss in profit or loss.
- D. The Group recognises the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(8) Financial assets at amortised cost

- A. Financial assets at amortised cost are those that meet all of the following criteria:
  - (a) The objective of the Group's business model is achieved by collecting contractual cash flows.
  - (b) The assets' contractual cash flows represent solely payments of principal and interest.
- B. On a regular way purchase or sale basis, financial assets at amortised cost are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs. Interest income from these financial assets is included in finance income using the effective interest method. A gain or loss is recognised in profit or loss when the asset is derecognised or impaired.
- D. The Group's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(9) Accounts receivable

Accounts receivable are loans that are created by the entity by selling goods or providing services to customers and are initially recognised at fair value. Accounts receivable are subsequently measured at amortised cost using the effective interest method, less impairment loss. Interest amortised using the effective interest method is recognised in profit or loss. However, short-term accounts and notes receivable without bearing interest are measured at transaction amount as the effect of discounting is immaterial.

(10) Financial assets at fair value through other comprehensive income

- A. Financial assets at fair value through other comprehensive income comprise equity securities

which are not held for trading, and for which the Group has made an irrevocable election at initial recognition to recognise changes in fair value in other comprehensive income.

- B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Group measures the financial assets at fair value plus transaction costs, and subsequently measured it at fair value. The changes in fair value of equity investments that were recognised in other comprehensive income are reclassified to retained earnings and are not reclassified to profit or loss following the derecognition of the investment. Dividends are recognised as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

(11) Impairment of financial assets

For financial assets at amortised cost, at each reporting date, the Group recognises the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognises the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable or contract assets that do not contain a significant financing component, the Group recognises the impairment provision for lifetime ECLs.

(12) Derecognition of financial assets

The Group derecognises a financial asset when the contractual rights to receive the cash flows from the financial asset expire.

(13) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted-average method. The cost of finished goods and work in progress comprises raw materials, direct labour, other direct costs and related production overheads. It excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realisable value. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

(14) Investments accounted for using equity method / associates

- A. Associates are all entities over which the Group has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for using equity method and are initially recognised at cost.
- B. The Group's share of its associates' post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Group's share of losses in an associate equals or

exceeds its interest in the associate, including any other unsecured receivables, the Group does not recognise further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.

- C. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Group's ownership percentage of the associate, the Group recognises the Group's share of change in equity of the associate in 'capital surplus' in proportion to its ownership.
- D. Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in the associates. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been adjusted where necessary to ensure consistency with the policies adopted by the Group.
- E. In the case that an associate issues new shares and the Group does not subscribe or acquire new shares proportionately, which results in a change in the Group's ownership percentage of the associate but maintains significant influence on the associate, then 'capital surplus' and 'investments accounted for using equity method' shall be adjusted for the increase or decrease of its share of equity interest. If the above condition causes a decrease in the Group's ownership percentage of the associate, in addition to the above adjustment, the amounts previously recognised in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately on the same basis as would be required if the relevant assets or liabilities were disposed of.
- F. When the Group disposes its investment in an associate and loses significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate, are reclassified to profit or loss, on the same basis as would be required if the relevant assets or liabilities were disposed of. If it retains significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately in accordance with the aforementioned approach.
- G. As of the balance sheet date, the Group conducts impairment tests on its associate companies that show signs of impairment. The entire carrying amount of the investment (including goodwill) is treated as a single asset, and its recoverable amount (the higher of value in use or fair value less costs of disposal) is compared with the carrying amount. Any recognised impairment loss is included in the carrying amount of the investment. Reversals of impairment losses are recognised to the extent that the recoverable amount of the investment subsequently increases.

(15) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost.
- B. Subsequent costs are included in the asset's book value or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will

flow to the Group and the cost of the item can be measured reliably. The book value of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

- C. Land is not depreciated. Other property, plant and equipment apply cost model and are depreciated using the straight-line method to allocate their cost over their estimated useful lives.
- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each balance sheet date. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

|                             |             |
|-----------------------------|-------------|
| Buildings and structures    | 10~40 years |
| Machinery and lab equipment | 3~20 years  |
| Office equipment            | 3~8 years   |
| Leasehold improvements      | 2~8 years   |
| Other equipment             | 3~5 years   |

(16) Operating leases (lessee) - right-of-use assets / lease liabilities

- A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Group. For short-term leases or leases of lowvalue assets, lease payments are recognised as an expense on a straight-line basis over the lease term.
- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of fixed payments, less any lease incentives receivable. The Group subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.
- C. At the commencement date, the right-of-use asset is stated at cost comprising the following:
  - (a) The amount of the initial measurement of lease liability;
  - (b) Any lease payments made at or before the commencement date;
  - (c) Any initial direct costs incurred by the lessee; and
  - (d) An estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset, restoring the site on which it is located or restoring the underlying asset to the condition required by the terms and conditions of the lease.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.

- D. Except for lease modifications that reduce the scope of the lease, the lessee shall reduce the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognise the difference between this reduction and the remeasured lease liability in profit or loss. For all other lease modifications, the lessee shall adjust the right-of-use asset accordingly to reflect the remeasured lease liability.

(17) Intangible assets

A. Trademark right

Trademark right is stated at cost and are amortised on a straight-line basis over the estimated useful life of 10 years.

B. Patent and acquired special technology

(a) Patents acquired in intellectual property right as equity are recognised at fair value at the acquisition date, and amortised on a straight-line basis over the estimated useful life of 17 years.

(b) If acquired by cash, it is recorded at acquisition cost; if acquired through business combination, it is recorded at fair value as measured at the acquisition date. The estimated useful life is 10 to 20 years, and it is amortised on a straight-line basis.

C. Computer software

Computer software is stated at cost and amortised on a straight-line basis over its estimated useful life of 1 to 3 years.

(18) Impairment of non-financial assets

The Group assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's book value exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. when the circumstances or reasons for recognising impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased book value due to reversal should not be more than what the depreciated or amortised historical cost would have been if the impairment had not been recognised.

(19) Borrowings

Borrowings comprise long-term and short-term bank borrowings and other short-term loans. Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

(20) Accounts payable and notes payable

Accounts payable from purchasing raw materials, goods or service on credit, are initially recognised at fair value less any transaction costs directly attributable to the issuance and subsequently measured at amortised cost using the effective interest method. Interest amortised using the effective interest method is recognised in profit or loss. However, short-term accounts payable without bearing interest are subsequently measured at transaction amount as the effect of discounting is immaterial.

(21) Derecognition of financial liabilities

A financial liability is derecognised when the obligation specified in the contract is either discharged or cancelled or expires.

(22) Provisions

Provisions (including decommissioning liabilities and those arising from termination of clinical trials) are recognised when the Group has a present legal or constructive obligation as a result of past events, and it is probable that an outflow of economic resources will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation on the balance sheet date, which is discounted using a pre-tax discount rate that reflects the current market assessments of the time value of money and the risks specific to the obligation. When discounting is used, the increase in the provision due to passage of time is recognised as interest expense. Provisions are not recognised for future operating losses.

(23) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expenses in that period when the employees render service.

B. Pensions - Defined contribution plans

For defined contribution plans, the contributions are recognised as pension expenses when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

C. Employees' compensation and directors' remuneration

Employees' compensation and directors' remuneration are recognised as expense and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates.

(24) Employee share-based payment

A. For the equity-settled share-based payment arrangements, the employee services received are measured at the fair value of the equity instruments granted at the grant date, and are recognised

as compensation cost over the vesting period, with a corresponding adjustment to equity. The fair value of the equity instruments granted shall reflect the impact of market vesting conditions and non-market vesting conditions. Compensation cost is subject to adjustment based on the service conditions that are expected to be satisfied and the estimates of the number of equity instruments that are expected to vest under the non-market vesting conditions at each balance sheet date. Ultimately, the amount of compensation cost recognised is based on the number of equity instruments that eventually vest.

**B. Restricted stocks:**

- (a) Restricted stocks issued to employees are measured at the fair value of the equity instruments granted at the grant date, and are recognised as compensation cost over the vesting period.
- (b) For restricted stocks where those stocks do not restrict distribution of dividends to employees and employees are not required to return the dividends received if they resign during the vesting period, the Group recognises the fair value of the dividends received by the employees who are expected to resign during the vesting period as compensation cost at the date of dividend declaration.
- (c) For restricted stocks where employees do not need to pay to acquire those stocks, the Company repurchases and retires the stock at no cost when the employees resign during the vesting period.

**(25) Income tax**

- A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.
- B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional 10% tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the shareholders resolve to retain the earnings.
- C. Deferred income tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their book value in the consolidated balance sheet. However, the deferred income tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss and does not give rise to equal taxable and deductible temporary differences. Deferred tax is provided on temporary differences arising on investments in subsidiaries and related parties

except where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

D. Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. At each balance sheet date, unrecognised and recognised deferred income tax assets are reassessed.

E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously.

Deferred income tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously.

F. A deferred tax asset shall be recognised for the carryforward of unused tax credits resulting from research and development expenditures, to the extent that it is possible that future taxable profit will be available against which the unused tax credits can be utilised.

#### (26) Share capital

A. Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or stock options are shown in equity as a deduction, net of tax, from the proceeds.

B. Where the Company repurchases the Company's equity share capital that has been issued, the consideration paid, including any directly attributable incremental costs (net of income taxes) is deducted from equity attributable to the Company's equity holders. Where such shares are subsequently reissued, the difference between their book value and any consideration received, net of any directly attributable incremental transaction costs and the related income tax effects, is included in equity attributable to the Company's equity holders.

#### (27) Revenue recognition

A. Revenue from licensing intellectual property

(a) The Group entered into a contract with a customer to grant a license of patents to the customer. Given the license is distinct from other promised goods or services in the contract, the Group recognises the revenue from licensing when the license is transferred to a customer either at a point in time or over time based on the nature of the license granted. The customer pays a non-refundable upfront fee upon signing of the contract, and makes milestone payments once each milestone is achieved. Revenue is recognised based on the transaction price. The nature of the Group's promise in granting a license is a promise to provide a right to access the Group's intellectual property if the Group undertakes activities that significantly affect the

patents to which the customer has rights, the customer is affected by the Group's activities and those activities do not result in the transfer of a good or a service to the customer as they occur. The royalties are recognised as revenue on a straight-line basis throughout the licensing period. In case the abovementioned conditions are not met, the nature of the Group's promise in granting a license is a promise to provide a right to use the Group's intellectual property and therefore the revenue is recognised when transferring the license to a customer at a point in time.

- (b) Some contracts require a sales-based royalty in exchange for a license of intellectual property. The Group recognises revenue when the performance obligation has been satisfied and the subsequent sale occurs.
- (c) The Group collaborates with customers in conducting the research and development of candidate drugs and performs analytical testing. Revenue is recognised when services are rendered and acknowledged by the customers.

#### B. Sales of goods

The Group researches, designs, develops, manufactures and sells protein new drugs and adjuvants. Revenue is measured at the fair value of the consideration received or receivable taking into account of business tax, returns, rebates and discounts for the sale of goods to external customers in the ordinary course of the Group's activities. Revenue arising from the sales of goods is recognised when the Group has delivered the goods to the customer, the amount of sales revenue can be measured reliably and it is probable that the future economic benefits associated with the transaction will flow to the entity. The delivery of goods is completed when the significant risks and rewards of ownership have been transferred to the customer, the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold, and the customer has accepted the goods based on the sales contract or there is objective evidence showing that all acceptance provisions have been satisfied.

#### C. Service revenue

The Group provides services including the development of analytical methods, method validation, sample stability testing, and collaboration with customers on development. Revenue is recognised when the outcome of the service transactions, such as the research and development of drug candidates and analytical testing, can be reliably estimated.

#### (28) Operating segments

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision-Maker, who is responsible for allocating resources and assessing performance of the operating segments.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the book value of assets and liabilities within the next financial year; and the related information is addressed below:

Impairment assessment of property, plant and equipment and right-of-use assets

The Group assesses impairment based on internal and external information and determines the separate cash flows of a specific group of assets, useful lives of assets and the future possible income and expenses, arising from the assets depending on industrial characteristics. In addition, the Group takes into account the fair value of assets. Any changes of economic circumstances or estimates due to the change of Group strategy might cause material impairment on assets in the future.

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

|                                       | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|---------------------------------------|--------------------------|--------------------------|
| Cash on hand                          | \$ 202                   | \$ 182                   |
| Checking accounts and demand deposits | 289,128                  | 471,868                  |
| Time deposits                         | 470,000                  | 1,260,000                |
|                                       | <u>\$ 759,330</u>        | <u>\$ 1,732,050</u>      |

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

B. The Group has no cash and cash equivalents pledged to others.

(2) Financial assets at fair value through profit or loss

| <u>Items</u>  | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|---|--------------------------|--------------------------|
| Current item:                                       |                          |                          |
| Financial assets mandatorily measured at fair value |                          |                          |
| Foreign listed stocks                               | \$ 1,394                 | \$ 1,394                 |
| Valuation adjustment                                | ( 1,394)                 | ( 1,305)                 |
|   | <u>\$ -</u>              | <u>\$ 89</u>             |

A. The Group recognised losses of \$89 and \$138 on financial assets at fair value through profit or loss for the years ended December 31, 2025 and 2024, respectively.

B. The Group has no financial assets at fair value through profit or loss pledged to others as collateral.

(3) Financial assets at fair value through other comprehensive income

| Items                | December 31, 2025 | December 31, 2024 |
|----------------------|-------------------|-------------------|
| Non-current item:    |                   |                   |
| Unlisted stocks      | \$ 27,181         | \$ 27,181         |
| Valuation adjustment | ( 19,726)         | ( 18,164)         |
|                      | \$ 7,455          | \$ 9,017          |

- A. The Group has elected to classify equity investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments amounted to \$7,455 and \$9,017 as at December 31, 2025 and 2024, respectively.
- B. Amounts recognised in other comprehensive income in relation to the financial assets at fair value through other comprehensive income are listed below:

|  | Years ended December 31, |            |
|--|--------------------------|------------|
|  | 2025                     | 2024       |
| <u>Equity instruments at fair value through other comprehensive income</u> |                          |            |
| Fair value change recognised in other comprehensive loss                   | (\$ 1,562)               | (\$ 1,604) |

- C. As at December 31, 2025 and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at fair value through other comprehensive income held by the Group was the closing book value.

(4) Financial assets at amortised cost

| Items   | December 31, 2025 | December 31, 2024 |
|---|-------------------|-------------------|
| Current items:  |                   |                   |
| Time deposits with original maturity period of more than three months | \$ 427,000        | \$ 1,398,700      |
| Non-current items:  |                   |                   |
| Pledged time deposits   | \$ 16,400         | \$ 12,900         |

- A. Amounts recognised in profit or loss in relation to financial assets at amortised cost are listed below:

|                 | Years ended December 31, |           |
|-----------------|--------------------------|-----------|
|                 | 2025                     | 2024      |
| Interest income | \$ 17,440                | \$ 16,697 |

- B. As at December 31, 2025 and 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at amortised cost held by the Group was the closing book value at the end of

the year.

C. Information relating to credit risk of financial assets at amortised cost is provided in Note 12(2).

The counterparties of the Group's investments in certificates of deposits are financial institutions with high credit quality, so the Group expects that the probability of counterparty default is remote.

D. The Group has pledged certain financial assets measured at amortised cost as collateral as described in Note 8.

(5) Prepayments

|   | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|---|--------------------------|--------------------------|
| Tax overpaid retained for offsetting the future tax payable | \$ 253,247               | \$ 227,333               |
| Others  | 55,216                   | 30,681                   |
|   | <u>\$ 308,463</u>        | <u>\$ 258,014</u>        |

(6) Investments accounted for using equity method

A. Details of investments accounted for using the equity method:

|  | <u>2025</u>       | <u>2024</u>       |
|--|-------------------|-------------------|
| At January 1   | \$ 937,933        | \$ 1,059,648      |
| Share of profit or loss of investments accounted for using equity method | ( 201,993)        | ( 233,177)        |
| Others   | 3,946             | 111,462           |
| At December 31   | <u>\$ 739,886</u> | <u>\$ 937,933</u> |

B. The basic information of the associate that is material to the Group is as follows:

| Company name         | Principal place of business | Shareholding ratio |                   | Nature of relationship                    | Method of measurement |
|----------------------|-----------------------------|--------------------|-------------------|---|-----------------------|
|                      |                             | December 31, 2025  | December 31, 2024 |   |                       |
| AP Biosciences, Inc. | Taiwan                      | 27.12%             | 27.32%            | Holding at least 20% of the voting rights | Equity method         |

C. The summarised financial information of the associate that is material to the Group is as follows:

Balance sheet

|                                 | AP Biosciences, Inc. |                     |
|---------------------------------|----------------------|---------------------|
|                                 | December 31, 2025    | December 31, 2024   |
| Current assets                  | \$ 1,221,591         | \$ 1,581,454        |
| Non-current assets              | 2,053,579            | 2,422,547           |
| Current liabilities             | ( 40,798)            | ( 36,536)           |
| Non-current liabilities         | ( 435,391)           | ( 520,414)          |
| Total net assets                | <u>\$ 2,798,981</u>  | <u>\$ 3,447,051</u> |
| Share in associate's net assets | \$ 759,191           | \$ 941,831          |
| Goodwill                        | 14,695               | 14,695              |
| Others                          | ( 34,000)            | ( 18,593)           |
| Book value of the associate     | <u>\$ 739,886</u>    | <u>\$ 937,933</u>   |

Statement of comprehensive income

|   | AP Biosciences, Inc.     |                     |
|---|--------------------------|---------------------|
|   | Years ended December 31, |                     |
|   | 2025                     | 2024                |
| Revenue                                       | \$ -                     | \$ -                |
| Loss for the year from continuing operations  | (\$ 739,708)             | (\$ 733,863)        |
| Other comprehensive income (loss), net of tax | 2,078                    | ( 1,082)            |
| Total comprehensive loss                      | <u>(\$ 737,630)</u>      | <u>(\$ 734,945)</u> |
| Dividends received from associates            | <u>\$ -</u>              | <u>\$ -</u>         |

D. The fair value of the Group's material associate, AP Biosciences, Inc., with quoted market prices as of December 31, 2025 and 2024 amounted to \$4,092,822 and \$1,150,700, respectively.

E. AP Biosciences, Inc.'s stock options were exercised in 2025 and 2024 and it increased its capital by issuing 20,000 thousand new common stocks in June 2024. However, the Company did not acquire shares proportionally to its interest. Consequently, the Company's shareholding ratio decreased to 27.12% and 27.32% as of December 31, 2025 and 2024, respectively.

F. The Group is the single major shareholder of AP Biosciences, Inc. Considering that the relevant power of the Group and related parties over AP Biosciences, Inc. does not enable the Group to direct relevant activities, the Group has no control but only has significant influence on the entity.

(7) Property, plant and equipment

The Group's property, plant and equipment are mainly for its own use. Details are as follows:

|  | <u>Buildings<br/>and structures</u> | <u>Machinery and<br/>lab equipment</u> | <u>Office<br/>equipment</u> | <u>Other<br/>equipment</u> | <u>Leasehold<br/>improvements</u> | <u>Unfinished<br/>construction and<br/>equipment under<br/>acceptance</u> | <u>Total</u>      |
|--|-------------------------------------|--|-----------------------------|----------------------------|-----------------------------------|---|-------------------|
| <u>At January 1, 2025</u>                  |                                     |  |                             |                            |                                   |   |                   |
| Cost                                       | \$ 344,485                          | \$ 1,034,563                           | \$ 43,405                   | \$ 2,205                   | \$ 276,845                        | \$ 10,071   | \$ 1,711,574      |
| Accumulated depreciation<br>and impairment | ( 124,997)                          | ( 708,986)                             | ( 31,488)                   | ( 1,588)                   | ( 59,910)                         | ( 5,962)  | ( 932,931)        |
|  | <u>\$ 219,488</u>                   | <u>\$ 325,577</u>                      | <u>\$ 11,917</u>            | <u>\$ 617</u>              | <u>\$ 216,935</u>                 | <u>\$ 4,109</u>   | <u>\$ 778,643</u> |
| <u>2025</u>                                |                                     |  |                             |                            |                                   |   |                   |
| At January 1                               | \$ 219,488                          | \$ 325,577                             | \$ 11,917                   | \$ 617                     | \$ 216,935                        | \$ 4,109  | \$ 778,643        |
| Additions (Note 3)                         | -                                   | 31,667                                 | 932                         | 150                        | 2,938                             | 1,653   | 37,340            |
| Reclassifications (Note 1)                 | -                                   | 6,124                                  | -                           | -                          | -                                 | ( 4,109)  | 2,015             |
| Disposal                                   | -                                   | -                                      | ( 300)                      | -                          | ( 82)                             | -   | ( 382)            |
| Depreciation                               | ( 15,903)                           | ( 93,980)                              | ( 4,951)                    | ( 215)                     | ( 37,059)                         | -   | ( 152,108)        |
| Net exchange differences                   | -                                   | ( 9)                                   | ( 17)                       | -                          | ( 6)                              | -   | ( 32)             |
| At December 31                             | <u>\$ 203,585</u>                   | <u>\$ 269,379</u>                      | <u>\$ 7,581</u>             | <u>\$ 552</u>              | <u>\$ 182,726</u>                 | <u>\$ 1,653</u>   | <u>\$ 665,476</u> |
| <u>At December 31, 2025</u>                |                                     |  |                             |                            |                                   |   |                   |
| Cost                                       | \$ 344,485                          | \$ 1,016,162                           | \$ 42,408                   | \$ 2,355                   | \$ 265,974                        | \$ 1,653  | \$ 1,673,037      |
| Accumulated depreciation<br>and impairment | ( 140,900)                          | ( 746,783)                             | ( 34,827)                   | ( 1,803)                   | ( 83,248)                         | -   | ( 1,007,561)      |
|  | <u>\$ 203,585</u>                   | <u>\$ 269,379</u>                      | <u>\$ 7,581</u>             | <u>\$ 552</u>              | <u>\$ 182,726</u>                 | <u>\$ 1,653</u>   | <u>\$ 665,476</u> |

|  | <u>Buildings<br/>and structures</u> | <u>Machinery and<br/>lab equipment</u> | <u>Office<br/>equipment</u> | <u>Other<br/>equipment</u> | <u>Leasehold<br/>improvements</u> | <u>Unfinished<br/>construction and<br/>equipment under<br/>acceptance</u> | <u>Total</u>      |
|--|-------------------------------------|--|-----------------------------|----------------------------|-----------------------------------|---|-------------------|
| <u>At January 1, 2024</u>                  |                                     |  |                             |                            |                                   |   |                   |
| Cost                                       | \$ 343,201                          | \$ 987,506                             | \$ 32,074                   | \$ 2,141                   | \$ 181,237                        | \$ 66,456   | \$ 1,612,615      |
| Accumulated depreciation<br>and impairment | ( 109,125)                          | ( 610,725)                             | ( 28,385)                   | ( 1,250)                   | ( 54,316)                         | ( 5,962)  | ( 809,763)        |
|  | <u>\$ 234,076</u>                   | <u>\$ 376,781</u>                      | <u>\$ 3,689</u>             | <u>\$ 891</u>              | <u>\$ 126,921</u>                 | <u>\$ 60,494</u>  | <u>\$ 802,852</u> |
| <u>2024</u>                                |                                     |  |                             |                            |                                   |   |                   |
| At January 1                               | \$ 234,076                          | \$ 376,781                             | \$ 3,689                    | \$ 891                     | \$ 126,921                        | \$ 60,494   | \$ 802,852        |
| Additions (Note 3)                         | 650                                 | 43,924                                 | 8,282                       | 64                         | 59,308                            | 3,649   | 115,877           |
| Reclassifications (Note 1)                 | 634                                 | 4,624                                  | 5,198                       | -                          | 58,030                            | ( 60,034)   | 8,452             |
| Disposals                                  | -                                   | -                                      | -                           | -                          | ( 577)                            | -   | ( 577)            |
| Depreciation                               | ( 15,872)                           | ( 99,759)                              | ( 5,278)                    | ( 338)                     | ( 26,755)                         | -   | ( 148,002)        |
| Net exchange differences                   | -                                   | 7                                      | 26                          | -                          | 8                                 | -   | 41                |
| At December 31                             | <u>\$ 219,488</u>                   | <u>\$ 325,577</u>                      | <u>\$ 11,917</u>            | <u>\$ 617</u>              | <u>\$ 216,935</u>                 | <u>\$ 4,109</u>   | <u>\$ 778,643</u> |
| <u>At December 31, 2024</u>                |                                     |  |                             |                            |                                   |   |                   |
| Cost                                       | \$ 344,485                          | \$ 1,034,563                           | \$ 43,405                   | \$ 2,205                   | \$ 276,845                        | \$ 10,071   | \$ 1,711,574      |
| Accumulated depreciation<br>and impairment | ( 124,997)                          | ( 708,986)                             | ( 31,488)                   | ( 1,588)                   | ( 59,910)                         | ( 5,962)  | ( 932,931)        |
|  | <u>\$ 219,488</u>                   | <u>\$ 325,577</u>                      | <u>\$ 11,917</u>            | <u>\$ 617</u>              | <u>\$ 216,935</u>                 | <u>\$ 4,109</u>   | <u>\$ 778,643</u> |

Note 1: The reclassifications resulted from a transfer from prepayments for business facilities (shown as 'other non-current asset') to property, plant, and equipment.

Note 2: Information about the property, plant and equipment that were pledged to others as collateral is provided in Note 8.

Note 3: Refer to Note 6(29).

Note 4: The Group's machinery and lab equipment, office equipment and leasehold improvements have been fully depreciated and then derecognised. Therefore, for the years ended December 31, 2025 and 2024, cost and accumulated depreciation of property, plant and equipment decreased by \$71,842, \$25,390, \$71,460 and \$24,813, respectively.

(8) Leasing arrangements - lessee

- A. The Group leases various assets including land and office space. Rental contracts are typically made for periods of 1 to 14 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions.
- B. Short-term leases with a lease term of 12 months or less comprise offices. Low-value assets comprise photocopiers.
- C. The book value of right-of-use assets and the depreciation are as follows:

|  | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|--|--------------------------|--------------------------|
|  | <u>Carrying amount</u>   | <u>Carrying amount</u>   |
| Land use right                               | \$ 74,099                | \$ 76,843                |
| Buildings                                    | 253,938                  | 309,008                  |
| Transportation equipment (Business vehicles) | 781                      | 591                      |
|  | <u>\$ 328,818</u>        | <u>\$ 386,442</u>        |

  

|  | <u>Years ended December 31,</u> |                     |
|--|---------------------------------|---------------------|
|  | <u>2025</u>                     | <u>2024</u>         |
|  | <u>Depreciation</u>             | <u>Depreciation</u> |
| Land use right                               | \$ 2,744                        | \$ 2,782            |
| Buildings                                    | 51,597                          | 52,264              |
| Transportation equipment (Business vehicles) | 334                             | 355                 |
|  | <u>\$ 54,675</u>                | <u>\$ 55,401</u>    |

- D. Information on profit or loss in relation to lease contracts is as follows:

|                                       | <u>Years ended December 31,</u> |             |
|---------------------------------------|---------------------------------|-------------|
|                                       | <u>2025</u>                     | <u>2024</u> |
| <u>Items affecting profit or loss</u> |                                 |             |
| Interest expense on lease liabilities | \$ 8,505                        | \$ 9,594    |
| Expense on short-term lease contracts | 2,746                           | 4,269       |
| Expense on leases of low-value assets | 577                             | 540         |
| Losses on lease modification          | 3,001                           | -           |

- E. The Group has recognised additions to right-of-use assets of \$1,125 and \$0 for the years ended December 31, 2025 and 2024, respectively.
- F. For the year ended December 31, 2024, the Group recognised a decrease in right-of-use assets and lease liabilities both in the amount of \$4,420 after remeasurement of lease liabilities due to lease modification.
- G. For the year ended December 31, 2025, as the lease contract was early terminated, the Group recognised a decrease in right-of-use assets and lease liabilities in the amount of \$3,828 and \$827, respectively. Loss on lease modification was shown as other gains and losses.

H. For the years ended December 31, 2025 and 2024, the Group's total cash outflow for leases were \$69,755 and \$60,149, of which \$57,927 and \$45,746 represents principal of lease liabilities, respectively.

I. Extension options

- (a) Extension options are included in the Group's lease contracts pertaining to land. These terms and conditions are the lessor's general practice and are in line with the plan and utilisation of the effective resources of the Group.
- (b) Extension options are included in the Group's lease contracts pertaining to certain offices based on the terms of the industrial park. The Group has the priority to lease the premises if it has no significant violation of the lease. These terms and conditions are in line with the plan and utilisation of the effective resources of the Group.
- (c) In determining the lease term, the Group takes into consideration all facts and circumstances that create an economic incentive to exercise an extension option. The assessment of lease period is reviewed if a significant event occurs which affects the assessment.

(9) Intangible assets

|                             | Patent                               |                                  |            |           | Total      |
|-----------------------------|--------------------------------------|----------------------------------|------------|-----------|------------|
|                             | OBI-3424<br>AKR1C3<br>enzyme prodrug | Trop 2<br>monoclonal<br>antibody | Trademarks | Software  |            |
| <u>At January 1, 2025</u>   |                                      |                                  |            |           |            |
| Cost                        | \$ 90,693                            | \$ 41,648                        | \$ 1,823   | \$ 13,903 | \$ 148,067 |
| Accumulated<br>amortisation | ( 66,508)                            | ( 12,495)                        | ( 956)     | ( 5,268)  | ( 85,227)  |
|                             | \$ 24,185                            | \$ 29,153                        | \$ 867     | \$ 8,635  | \$ 62,840  |
| <u>2025</u>                 |                                      |                                  |            |           |            |
| At January 1                | \$ 24,185                            | \$ 29,153                        | \$ 867     | \$ 8,635  | \$ 62,840  |
| Additions                   | -                                    | -                                | 20         | 4,379     | 4,399      |
| Amortisation                | ( 9,069)                             | ( 4,165)                         | ( 183)     | ( 6,962)  | ( 20,379)  |
| At December 31              | \$ 15,116                            | \$ 24,988                        | \$ 704     | \$ 6,052  | \$ 46,860  |
| <u>At December 31, 2025</u> |                                      |                                  |            |           |            |
| Cost                        | \$ 90,693                            | \$ 41,648                        | \$ 1,843   | \$ 15,824 | \$ 150,008 |
| Accumulated<br>amortisation | ( 75,577)                            | ( 16,660)                        | ( 1,139)   | ( 9,772)  | ( 103,148) |
|                             | \$ 15,116                            | \$ 24,988                        | \$ 704     | \$ 6,052  | \$ 46,860  |

|                               | Patent  |   |                                  |                 |                 |                  |
|-------------------------------|---|---|----------------------------------|-----------------|-----------------|------------------|
|                               | OBI-833<br>Next-<br>generation<br>cancer<br>vaccine | OBI-3424<br>AKR1C3<br>enzyme<br>prodrug | Trop 2<br>monoclonal<br>antibody | Trademarks      | Software        | Total            |
| <u>At January 1, 2024</u>     |   |   |                                  |                 |                 |                  |
| Cost                          | \$ 1,500  | \$ 90,693                               | \$ 41,648                        | \$ 1,823        | \$ 9,380        | \$ 145,044       |
| Accumulated<br>amortisation   | ( 1,500)  | ( 57,439)                               | ( 8,330)                         | ( 774)          | ( 3,817)        | ( 71,860)        |
|                               | <u>\$ -</u>   | <u>\$ 33,254</u>                        | <u>\$ 33,318</u>                 | <u>\$ 1,049</u> | <u>\$ 5,563</u> | <u>\$ 73,184</u> |
| <u>2024</u>                   |   |   |                                  |                 |                 |                  |
| At January 1                  | \$ -  | \$ 33,254                               | \$ 33,318                        | \$ 1,049        | \$ 5,563        | \$ 73,184        |
| Additions                     | -   | -                                       | -                                | -               | 6,321           | 6,321            |
| Reclassifications<br>(Note 1) | -   | -                                       | -                                | -               | 2,186           | 2,186            |
| Amortisation                  | -   | ( 9,069)                                | ( 4,165)                         | ( 182)          | ( 5,435)        | ( 18,851)        |
| At December 31                | <u>\$ -</u>   | <u>\$ 24,185</u>                        | <u>\$ 29,153</u>                 | <u>\$ 867</u>   | <u>\$ 8,635</u> | <u>\$ 62,840</u> |
| <u>At December 31, 2024</u>   |   |   |                                  |                 |                 |                  |
| Cost                          | \$ -  | \$ 90,693                               | \$ 41,648                        | \$ 1,823        | \$ 13,903       | \$ 148,067       |
| Accumulated<br>amortisation   | -   | ( 66,508)                               | ( 12,495)                        | ( 956)          | ( 5,268)        | ( 85,227)        |
|                               | <u>\$ -</u>   | <u>\$ 24,185</u>                        | <u>\$ 29,153</u>                 | <u>\$ 867</u>   | <u>\$ 8,635</u> | <u>\$ 62,840</u> |

Note 1: The reclassifications resulted from a transfer from prepayments (shown as ‘other non-current asset’) to intangible assets.

Note 2: The Group’s patent and software has been fully amortised and then derecognised. Therefore, for the years ended December 31, 2025 and 2024, cost and accumulated amortisation of intangible assets both decreased by \$2,458 and \$5,484, respectively.

A. Details of amortisation on intangible assets are as follows:

|                                   | Years ended December 31, |                  |
|-----------------------------------|--------------------------|------------------|
|                                   | 2025                     | 2024             |
| Administrative expenses           | \$ 3,893                 | \$ 2,591         |
| Research and development expenses | 16,486                   | 16,260           |
|                                   | <u>\$ 20,379</u>         | <u>\$ 18,851</u> |

B. In 2010, the Company acquired patents named “next-generation cancer vaccine” (OBI-833) and “reagent for cancer screening” (OBI-868). The contract states that the Company must pay royalty fees based on the achieved milestones. In 2013, the Company paid royalty fees of \$1,500 separately for both projects. The Company decided to terminate OBI-833, a novel cancer active immunotherapy, on May 12, 2025, and notified Academia Sinica to terminate the licensing agreement in accordance with the termination clause in the third quarter of 2025.

C. On May 31, 2017, the Company entered into an agreement with Threshold Pharmaceuticals, Inc. to acquire the global IP right (excluding Mainland China, Hong Kong, Macao, Taiwan, Japan,

South Korea, Singapore, Malaysia, Thailand, Turkey and India) and patent regarding the innovative micromolecule drug TH-3424, which was then renamed OBI-3424.

D. On December 8, 2021, the Company and Biosion, Inc. (hereafter referred to as “Biosion”) entered into an exclusive authorisation contract of humanised Trop2 monoclonal antibody (product No. BSI-04702). The authorisation includes global exclusive right, except for Mainland China, Hong Kong and Macao. Under the contract, the Company will pay signing bonus to Biosion, milestone payment based on the progress of the research and development, and royalties based on a certain percentage of sales amount after the product has been launched in the market. As of December 31, 2025, the Company has not launched any products related to the aforementioned technology license. The maximum unpaid royalties for the subsequent trial phases as stipulated in the contract totaled USD 69,000 thousand.

E. The Group has no intangible assets pledged to others.

(10) Short-term borrowings

| <u>Type of borrowings</u> | <u>December 31, 2025</u> | <u>Interest rate</u> | <u>Collateral</u>  |
|---------------------------|--------------------------|----------------------|--|
| Bank borrowings           |                          |                      |  |
| Secured borrowings        |                          |                      | Buildings located at No. 19, Shengyi 5th Rd., Zhubei City, Hsinchu County (Note) |
|                           | <u>\$ 50,353</u>         | 2.31%                |  |
| <u>Type of borrowings</u> | <u>December 31, 2024</u> | <u>Interest rate</u> | <u>Collateral</u>  |
| Bank borrowings           |                          |                      |  |
| Secured borrowings        |                          |                      | Buildings located at No. 19, Shengyi 5th Rd., Zhubei City, Hsinchu County (Note) |
|                           | <u>\$ 412</u>            | 2.31%                |  |

Note : Refer to Note 8 for details.

(11) Long-term borrowings

| Type of borrowings                   | Borrowing period and repayment term   | Interest rate | Collateral | December 31, 2025 | December 31, 2024 |
|--------------------------------------|---|---------------|------------|-------------------|-------------------|
| Long-term bank borrowings            |   |               |            |                   |                   |
| Secured borrowings                   | Borrowing period is from January 31, 2024 to January 31, 2027; interest is payable monthly (Note 2) | Note 3        | Note 1     | \$ 14,583         | \$ 26,250         |
| Secured borrowings                   | Borrowing period is from May 17, 2024 to May 17, 2027; interest is payable monthly (Note 4)         | Note 5        | Note 1     | 33,636            | 56,061            |
| Non-financial institution borrowings |   |               |            |                   |                   |
| Secured borrowings                   | Borrowing period is from April 30, 2025 to April 30, 2027; interest is payable monthly (Note 6)     | Note 6        | Note 1     | 6,746             | -                 |
| Secured borrowings                   | Borrowing period is from May 15, 2025 to May 15, 2027; interest is payable monthly (Note 7)         | Note 7        | Note 1     | 46,363            | -                 |
| Less: Current portion                |   |               |            | ( 71,870)         | ( 34,091)         |
|                                      |   |               |            | <u>\$ 29,458</u>  | <u>\$ 48,220</u>  |

Note 1: Refer to Note 8 for details.

Note 2: The Group negotiated the borrowing contract with the bank whereby the principal is payable quarterly starting from April 2024.

Note 3: It was calculated based on the floating interest rate on the facility of two-year time deposits less than NT\$5 million, as posted by the Chunghwa Post Co., Ltd. plus 0.5%. On December 31, 2025 and 2024, the interest rates were all 2.22%.

Note 4: The Group negotiated the borrowing contract with the bank whereby the principal is payable quarterly starting from August 2024.

Note 5: It was calculated based on the floating interest rate on the facility of one-year time deposits, as posted by the Mega International Commercial Bank plus 0.8%. On December 31, 2025 and 2024, the interest rates were all 2.52%.

Note 6: The Group negotiated the borrowing contract with Chailease Specialty Finance Co., Ltd. whereby the principal is payable monthly starting from May 2025. The Group issued monthly post-dated checks as collateral, and the effective interest rate for the loan was 7.41%.

Note 7: The Group negotiated the borrowing contract with Chailease Specialty Finance Co., Ltd. whereby the principal is payable monthly starting from June 2025. The Group issued monthly post-dated checks as collateral, and the effective interest rate for the loan was 6.78%.

(12) Other payables

|                                      | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|--------------------------------------|--------------------------|--------------------------|
| Accrued clinical trials cost         | \$ 36,601                | \$ 77,700                |
| Accrued consulting and service fee   | 32,577                   | 31,491                   |
| Wages and salaries payable           | 13,637                   | 13,689                   |
| Accrued clinical materials expense   | 4,879                    | 96,973                   |
| Outsourced research expenses payable | 4,490                    | 32,042                   |
| Payable on equipment                 | 2,869                    | 8,490                    |
| Others                               | 21,817                   | 37,448                   |
|                                      | <u>\$ 116,870</u>        | <u>\$ 297,833</u>        |

(13) Provisions

|                       | <u>Decommissioning liabilities</u> | <u>Others (Note)</u> | <u>Total</u>     |
|-----------------------|------------------------------------|----------------------|------------------|
| At January 1, 2025    | \$ 6,008                           | \$ -                 | \$ 6,008         |
| Additional provisions | 129                                | 166,234              | 166,363          |
| Used                  | -                                  | (116,948)            | (116,948)        |
| At December 31, 2025  | <u>\$ 6,137</u>                    | <u>\$ 49,286</u>     | <u>\$ 55,423</u> |
|                       | <u>Decommissioning liabilities</u> | <u>Others (Note)</u> | <u>Total</u>     |
| At January 1, 2024    | \$ 5,882                           | \$ -                 | \$ 5,882         |
| Additional provisions | 126                                | -                    | 126              |
| At December 31, 2024  | <u>\$ 6,008</u>                    | <u>\$ -</u>          | <u>\$ 6,008</u>  |

The provision analysis is as follows:

|             | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|-------------|--------------------------|--------------------------|
| Current     | \$ 49,286                | \$ -                     |
| Non-current | \$ 6,137                 | \$ 6,008                 |

Note : The Company's Phase III clinical trial of its active cancer immunotherapy, OBI-822, for

the triple negative breast cancer, received recommendation from the Data and Safety Monitoring Board (DSMB) in April 2025 regarding the second interim analysis, that the Company should terminate the study. Following thorough internal evaluation, the Company has decided to follow the DSMB recommendation and to terminate the trial. Further, the Company will redirect its resources to focus on the development of next-generation Antibody-Drug Conjugates (ADCs). The Company's active cancer immunotherapy, OBI-833, was terminated upon the approval of the Board of Directors on May 12, 2025, due to rapidly tightened competition in the pharmaceuticals market and unpredictability of clinical trials. Further, the Company will redirect its resources to focus on the development of next-generation Antibody-Drug Conjugates (ADCs). Based on the contracted research agreement with CROs (Contract research organizations) and historical trial-related cost data, the Company estimates the total costs associated with the termination of the trial to be \$166,234 and has recognised provisions in the second quarter of 2025.

(14) Pension

- A. The Company and its domestic subsidiaries have established a defined contribution pension plan (the "New Plan") under the Labor Pension Act (the "Act"), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company and its domestic subsidiaries contribute monthly an amount based on 6% of the employees' monthly salaries and wages to the employees' individual pension accounts at the Bureau of Labor Insurance. The benefits accrued are paid monthly or in lump sum upon termination of employment. The pension costs under the defined contribution pension plans of the Group for the years ended December 31, 2025 and 2024 were \$15,035 and \$15,845, respectively.
- B. OBI Pharma Australia Pty Ltd. and OBI Pharma Limited were not required to set up a policy for employee pension plans. Odeon Therapeutics (Cayman) Limited, Odeon Therapeutics (Hong Kong) Limited and Odeon Therapeutics (Shanghai) Limited did not have any employees and thus did not recognise pension costs. For the pension plan based on local government regulations, OBI Pharma USA, Inc. recognised pension costs of \$3,788 and \$3,647 for the years ended December 31, 2025 and 2024, respectively.

(15) Share-based payment

A. Information on share-based payments made by the Company and the subsidiaries is as follows:

(a) The options were granted to qualified employees of the Company and the subsidiaries which the Company holds over 50% equity interest by issuing new shares of the Company when exercised. The options are valid for 10 years. The major contents were as follows:

| Type of agreement  | Grant date | No. of units | Subscription share per unit | Vesting conditions   | Weighted-average remaining contract period (years) |
|--|------------|--------------|-----------------------------|--|--|
| Employee stock option plan<br>(Note 1)                               | 2014.02.21 | 1,744,000    | 1                           | After two years of service, employees can exercise options at a certain percentage based on the schedule                             | -  |
| "  | 2014.03.26 | 575,000      | 1                           | "  | -  |
| "  | 2015.05.06 | 2,861,000    | 1                           | "  | -  |
| "  | 2015.08.04 | 75,000       | 1                           | "  | -  |
| "  | 2015.11.06 | 353,000      | 1                           | "  | -  |
| "  | 2015.12.15 | 13,000       | 1                           | "  | -  |
| "  | 2016.03.25 | 1,377,000    | 1                           | "  | 0.23   |
| "  | 2017.03.09 | 3,145,000    | 1                           | "  | 1.19   |
| "  | 2017.05.12 | 20,000       | 1                           | "  | 1.36   |
| "  | 2017.08.11 | 20,000       | 1                           | "  | 1.61   |
| "  | 2017.11.10 | 130,000      | 1                           | "  | 1.86   |
| "  | 2018.01.19 | 1,685,000    | 1                           | "  | 2.05   |
| "  | 2019.09.06 | 1,125,000    | 1                           | "  | 3.68   |
| "  | 2019.11.08 | 385,000      | 1                           | "  | 3.85   |
| "  | 2020.08.05 | 510,000      | 1                           | "  | 4.59   |
| "  | 2021.11.05 | 3,859,000    | 1                           | "  | 5.85   |
| "  | 2022.03.18 | 320,000      | 1                           | "  | 6.21   |
| "  | 2022.05.06 | 143,000      | 1                           | "  | 6.35   |
| "  | 2022.08.08 | 639,000      | 1                           | "  | 6.60   |
| "  | 2023.08.07 | 725,000      | 1                           | "  | 7.60   |
| "  | 2024.03.11 | 200,000      | 1                           | "  | 8.19   |
| "  | 2024.05.10 | 50,000       | 1                           | "  | 8.36   |
| "  | 2024.08.02 | 1,800,000    | 1                           | "  | 8.59   |
| "  | 2025.03.10 | 175,000      | 1                           | "  | 9.19   |
| "  | 2025.05.12 | 50,000       | 1                           | "  | 9.36   |
| Cash capital increase reserved for employee subscription<br>(Note 1) | 2024.10.14 | 1,500,000    | 1                           | Immediately vested   | -  |
| Restricted stocks to employees<br>(Note 2)                           | 2022.10.25 | 160,000      | 1                           | After two years of service and achieving certain performance level, restricted stocks can be vested at a certain percentage (Note 3) | -  |

Note 1: The above share-based payment arrangements are equity-settled.

Note 2: The restricted shares issued by the Company cannot be sold, pledged, transferred, donated, collateralized, or disposed in any other method during the vesting period. However, the rights to distribution of dividends, bonuses and capital surplus, and subscription rights to cash capital increase are not restricted.

Note 3: The employee restricted shares granted to an executive can only be vested if (1) the executive remains employed by the Company on the last date of each vesting period; (2) during the vesting period, the executive may not breach any agreement with the Company or violate the Company's work rules; and (3) executive performance metrics set up by the Company are met (that is, a performance rating of at least "Exceed" or above for the year immediately preceding the expiration of each vesting period.).

The vesting conditions of granted employee restricted shares are as follows:

- a. 50% of restricted shares are vested to employees who remain employed by the Company two years from the grant date;
- b. 25% of restricted shares are vested to employees who remain employed by the Company three years from the grant date;
- c. 25% of restricted shares are vested to employees who remain employed by the Company four years from the grant date.

(b) The options were granted to qualified employees of the subsidiary, Amaran Biotechnology Inc., issuing new shares of the subsidiary when exercised. The options are valid for 10 years. The major contents were as follows:

| Type of agreement                 | Grant date | No. of units | Subscription share per unit | Vesting conditions  | Weighted-average remaining contract period (years) |
|-----------------------------------|------------|--------------|-----------------------------|---|--|
| Employee stock option plan (Note) | 2014.01.15 | 920          | 1,000                       | After one year of service, employees can exercise options at a certain percentage based on the schedule | -  |
| "                                 | 2014.05.02 | 310          | 1,000                       | "   | -  |
| "                                 | 2014.09.03 | 270          | 1,000                       | "   | -  |
| "                                 | 2015.02.12 | 255          | 1,000                       | "   | -  |
| "                                 | 2015.05.27 | 300          | 1,000                       | "   | -  |
| "                                 | 2015.09.09 | 70           | 1,000                       | "   | -  |
| "                                 | 2015.12.15 | 235          | 1,000                       | "   | -  |
| "                                 | 2016.03.02 | 2,382        | 1,000                       | "   | 0.16   |
| "                                 | 2016.09.02 | 45           | 1,000                       | "   | 0.67   |
| "                                 | 2017.01.01 | 179          | 1,000                       | "   | 1.00   |
| "                                 | 2017.04.01 | 34           | 1,000                       | "   | 1.24   |

| Type of agreement                 | Grant date | No. of units | Subscription share per unit | Vesting conditions  | Weighted-average remaining contract period (years) |
|-----------------------------------|------------|--------------|-----------------------------|---|--|
| Employee stock option plan (Note) | 2017.06.01 | 60           | 1,000                       | After one year of service, employees can exercise options at a certain percentage based on the schedule | 1.41   |
| "                                 | 2018.03.23 | 1,090        | 1,000                       | "   | 2.22   |
| "                                 | 2018.09.18 | 60           | 1,000                       | "   | 2.71   |
| "                                 | 2019.01.01 | 65           | 1,000                       | "   | 3.00   |
| "                                 | 2019.03.01 | 65           | 1,000                       | "   | 3.16   |
| "                                 | 2019.10.01 | 210          | 1,000                       | "   | 3.75   |
| "                                 | 2020.04.01 | 250          | 1,000                       | "   | 4.25   |
| "                                 | 2020.05.01 | 120          | 1,000                       | "   | 4.33   |
| "                                 | 2021.07.01 | 110          | 1,000                       | "   | 5.50   |
| "                                 | 2021.08.01 | 115          | 1,000                       | "   | 5.58   |
| "                                 | 2021.09.01 | 15           | 1,000                       | "   | 5.67   |
| "                                 | 2021.10.01 | 1,139        | 1,000                       | "   | 5.75   |
| "                                 | 2022.04.01 | 135          | 1,000                       | "   | 6.25   |
| "                                 | 2022.05.01 | 60           | 1,000                       | "   | 6.33   |
| "                                 | 2022.06.01 | 15           | 1,000                       | "   | 6.41   |
| "                                 | 2023.01.01 | 41           | 1,000                       | "   | 7.00   |
| "                                 | 2024.01.01 | 1,900        | 1,000                       | "   | 8.00   |
| "                                 | 2024.06.01 | 30           | 1,000                       | "   | 8.42   |
| "                                 | 2024.08.01 | 20           | 1,000                       | "   | 8.58   |
| "                                 | 2024.10.01 | 30           | 1,000                       | "   | 8.75   |
| "                                 | 2024.12.01 | 20           | 1,000                       | "   | 8.92   |

Note: The above share-based payment arrangements are equity-settled.

- (c) The options were granted by the subsidiary, Obigen Pharma, Inc., to qualified employees of the subsidiary and the Company by issuing new shares of the subsidiary when exercised. The options are valid for 8-10 years. The major contents were as follows:

| Type of agreement                 | Grant date | No. of units | Subscription share per unit | Vesting conditions   | Weighted-average remaining contract period (years) |
|-----------------------------------|------------|--------------|-----------------------------|--|--|
| Employee stock option plan (Note) | 2021.12.09 | 1,568,000    | 1                           | After two years of service, employees can exercise options at a certain percentage based on the schedule | 5.95   |
| "                                 | 2022.03.23 | 163,000      | 1                           | "  | 6.22   |
| "                                 | 2022.10.28 | 269,000      | 1                           | "  | 6.82   |
| "                                 | 2023.05.26 | 427,000      | 1                           | "  | 7.40   |
| "                                 | 2023.05.26 | 1,855,000    | 1                           | After six months of service, employees can exercise options  | 5.40   |

| Type of agreement                 | Grant date | No. of units | Subscription share per unit | Vesting conditions   | Weighted-average remaining contract period (years) |
|-----------------------------------|------------|--------------|-----------------------------|--|--|
| Employee stock option plan (Note) | 2023.12.06 | 573,000      | 1                           | After two years of service, employees can exercise options at a certain percentage based on the schedule | 7.93   |
| "                                 | 2024.03.20 | 445,000      | 1                           | After six months of service, employees can exercise options  | 6.22   |
| "                                 | 2024.12.10 | 1,014,000    | 1                           | After two years of service, employees can exercise options at a certain percentage based on the schedule | 8.94   |
| "                                 | 2025.02.18 | 1,000,000    | 1                           | "  | 9.13   |
| "                                 | 2025.10.02 | 986,000      | 1                           | "  | 9.75   |

Note: The above share-based payment arrangement is equity-settled.

B.Details of the share-based payment arrangements are as follows:

(a) The Company's employee stock option plan:

|   | Years ended December 31, |  |                   |  |
|---|--------------------------|--|-------------------|--|
|   | 2025                     |  | 2024              |  |
|   | No. of units             | Weighted-average exercise price (in dollars) | No. of units      | Weighted-average exercise price (in dollars) |
| Options outstanding at beginning of the year          | 10,945,287               | \$ 286.10                                    | 10,610,595        | \$ 339.10                                    |
| Options granted                                       | 225,000                  | 108.36                                       | 2,050,000         | 120.64                                       |
| Options forfeited or expired                          | ( 3,214,635)             | 308.48                                       | ( 1,715,308)      | 337.22                                       |
| Options outstanding at end of the year                | <u>7,955,652</u>         | 272.04                                       | <u>10,945,287</u> | 286.10                                       |
| Options exercisable at end of the year                | <u>5,895,434</u>         |  | <u>7,341,885</u>  |  |
| Options authorised but not granted at end of the year | <u>-</u>                 |  | <u>225,000</u>    |  |

(b) Restricted stocks to employees:

|                                      | Years ended December 31, |               |
|--------------------------------------|--------------------------|---------------|
|                                      | 2025                     | 2024          |
|                                      | No. of shares            | No. of shares |
| Stocks outstanding at January 1      | 80,000                   | 160,000       |
| Stock options vested during the year | ( 60,000)                | -             |
| Stocks cancelled (Note)              | ( 10,000)                | ( 80,000)     |
| Stocks outstanding at December 31    | <u>10,000</u>            | <u>80,000</u> |

Note: In 2025, 10,000 shares were cancelled in proportion to the capital reduction ratio pursuant to the terms of restricted stock plan.

(c) The employee stock option plan of subsidiary, Amaran Biotechnology Inc.:

|   | Years ended December 31, |  |              |  |
|---|--------------------------|--|--------------|--|
|   | 2025                     |  | 2024         |  |
|   | No. of units             | Weighted-average exercise price (in dollars) | No. of units | Weighted-average exercise price (in dollars) |
| Options outstanding at beginning of the year          | 4,520                    | \$ 29.33                                     | 3,293        | \$ 35.66                                     |
| Options granted                                       | -                        | -  | 2,000        | 20.00  |
| Options exercisable                                   | ( 18)                    | 20.00  | -            | -  |
| Options forfeited or expired                          | ( 1,464)                 | 34.15  | ( 773)       | 32.12  |
| Options outstanding at end of the year                | <u>3,038</u>             | 27.07  | <u>4,520</u> | 29.33  |
| Options exercisable at end of the year                | <u>2,238</u>             |  | <u>2,877</u> |  |
| Options authorised but not granted at end of the year | <u>2,000</u>             |  | <u>-</u>     |  |

(d) The employee stock option plan of subsidiary, Obigen Pharma, Inc.:

|   | Years ended December 31, |  |                  |  |
|---|--------------------------|--|------------------|--|
|   | 2025                     |  | 2024             |  |
|   | No. of units             | Weighted-average exercise price (in dollars) | No. of units     | Weighted-average exercise price (in dollars) |
| Options outstanding at beginning of the year          | 5,520,500                | \$ 22.17                                     | 4,247,000        | \$ 20.00                                     |
| Options granted                                       | 1,986,000                | 32.00  | 1,459,000        | 28.34  |
| Options exercisable                                   | ( 1,027,250)             | 20.00  | -                | -  |
| Options forfeited or expired                          | ( 770,000)               | 24.52  | ( 185,500)       | 21.04  |
| Options outstanding at end of the year                | <u>5,709,250</u>         | 25.68  | <u>5,520,500</u> | 22.17  |
| Options exercisable at end of the year                | <u>2,687,750</u>         |  | <u>3,211,250</u> |  |
| Options authorised but not granted at end of the year | <u>-</u>                 |  | <u>1,986,000</u> |  |

- C. The Company has no stock option exercised for the years ended December 31, 2025 and 2024. The subsidiary's, Obigen Pharma Inc.'s, weighted average stock price on the execution date for stock options exercised for the year ended December 31, 2025 was \$21.81 (in dollars) and no stock options were exercised for the year ended December 31, 2024. The subsidiary's, Amaran Biotechnology Inc.'s, weighted average stock price on the execution date for stock options exercised for the year ended December 31, 2025 was \$20 (in dollars) and no stock options were exercised for the year ended December 31, 2024.
- D. As of December 31, 2025 and 2024, the range of exercise prices of the Company's stock options outstanding were \$78.1~\$618.2 (in dollars) and \$117.4~\$1,019.4 (in dollars), respectively. The range of exercise prices of the subsidiary's, Amaran Biotechnology Inc.'s, stock options outstanding was both \$15~\$70 (in dollars). The exercise price of the subsidiary's, Obigen Pharma, Inc.'s, stock options outstanding were both \$20~\$32 (in dollars) .
- E. The fair value of stock options granted on grant date is measured using the Black-Scholes option-pricing model. Relevant information is as follows:

(a) The Company's employee stock option plan:

| Type of agreement  | Grant date | Underlying market value on measurement date (in dollars) | Exercise price per share (in dollars) (Note 3) | Expected volatility (Note 1) | Expected option life | Expected dividend yield | Risk-free interest rate | Fair value per unit (in dollars) |
|--|------------|--|--|------------------------------|----------------------|-------------------------|-------------------------|----------------------------------|
| Employee stock option plan                               | 2014.02.21 | \$ 231.4   | \$ 191.1                                       | 47.62%                       | 6.375 years          | 0%                      | 1.34%                   | \$ 114.80                        |
| "  | 2014.03.26 | 215.0  | 201.0  | 46.54%                       | 6.375 years          | 0%                      | 1.38%                   | 97.07                            |
| "  | 2015.05.06 | 334.0  | 252.9  | 44.46%                       | 6.375 years          | 0%                      | 1.33%                   | 150.18                           |
| "  | 2015.08.04 | 283.0  | 219.6  | 43.90%                       | 6.375 years          | 0%                      | 1.21%                   | 125.27                           |
| "  | 2015.11.06 | 422.0  | 310.4  | 44.11%                       | 6.375 years          | 0%                      | 1.01%                   | 186.00                           |
| "  | 2015.12.15 | 727.0  | 509.7  | 45.44%                       | 6.375 years          | 0%                      | 0.99%                   | 328.28                           |
| "  | 2016.03.25 | 420.0  | 618.2  | 47.70%                       | 6.375 years          | 0%                      | 0.72%                   | 195.43                           |
| "  | 2017.03.09 | 326.0  | 615.4  | 50.01%                       | 6.375 years          | 0%                      | 1.11%                   | 159.90                           |
| "  | 2017.05.12 | 261.0  | 492.8  | 49.51%                       | 6.375 years          | 0%                      | 0.96%                   | 126.34                           |
| "  | 2017.08.11 | 191.0  | 360.6  | 48.61%                       | 6.375 years          | 0%                      | 0.82%                   | 90.60                            |
| "  | 2017.11.10 | 169.0  | 319.0  | 48.44%                       | 6.375 years          | 0%                      | 0.81%                   | 79.91                            |
| "  | 2018.01.19 | 170.5  | 322.0  | 48.61%                       | 6.375 years          | 0%                      | 0.88%                   | 81.04                            |
| "  | 2019.09.06 | 144.0  | 275.4  | 45.65%                       | 6.375 years          | 0%                      | 0.62%                   | 64.29                            |
| "  | 2019.11.08 | 131.0  | 250.6  | 45.03%                       | 6.375 years          | 0%                      | 0.65%                   | 57.88                            |
| "  | 2020.08.05 | 120.0  | 229.6  | 45.37%                       | 6.375 years          | 0%                      | 0.37%                   | 52.76                            |
| "  | 2021.11.05 | 108.0  | 206.8  | 45.03%                       | 6.375 years          | 0%                      | 0.45%                   | 47.33                            |
| "  | 2022.03.18 | 110.0  | 210.6  | 44.11%                       | 6.375 years          | 0%                      | 0.79%                   | 48.06                            |
| "  | 2022.05.06 | 118.5  | 232.4  | 43.61%                       | 6.375 years          | 0%                      | 1.17%                   | 52.11                            |
| "  | 2022.08.08 | 79.0   | 155.0  | 43.15%                       | 6.375 years          | 0%                      | 1.10%                   | 34.33                            |
| "  | 2023.08.07 | 84.6   | 166.0  | 42.23%                       | 6.375 years          | 0%                      | 1.11%                   | 36.12                            |
| "  | 2024.03.11 | 63.8   | 125.2  | 40.73%                       | 6.375 years          | 0%                      | 1.20%                   | 26.53                            |
| "  | 2024.05.10 | 61.7   | 121.0  | 39.92%                       | 6.375 years          | 0%                      | 1.56%                   | 25.68                            |
| "  | 2024.08.02 | 59.9   | 177.4  | 39.60%                       | 6.375 years          | 0%                      | 1.49%                   | 24.69                            |
| "  | 2025.03.10 | 58.5   | 117.0  | 39.28%                       | 6.375 years          | 0%                      | 1.66%                   | 24.15                            |
| "  | 2025.05.12 | 39.1   | 78.1   | 40.30%                       | 6.375 years          | 0%                      | 1.66%                   | 16.30                            |
| Cash capital increase reserved for employee subscription | 2024.10.14 | 67.8   | 64.0   | 50.83%                       | 0.060 years          | 0%                      | 1.22%                   | 5.55                             |
| Restricted stocks to employees                           | 2022.10.25 | 66.0   |  |                              | Note 2               |                         |                         | 66.00                            |

Note 1: Expected price volatility rate was estimated by using the average price volatility of similar listed and OTC companies within the appropriate period and the Company's historical transaction data since its shares traded on the Emerging Stock Market.

Note 2: The Company issued employee restricted shares with a par value of NT\$10 (in dollars) per share, the issuance price was NT\$0 (at no cost), and the fair value was measured at the closing price of the Company's share at the grant date.

Note 3: The exercise price was adjusted in accordance with the employee stock option plan.

(b) The employee stock option plan of subsidiary, Amaran Biotechnology Inc.:

| Type of agreement          | Grant date | Underlying market value on measurement date (in dollars) | Exercise price per share (in dollars) | Expected volatility (Note) | Expected option life | Expected dividend yield | Risk-free interest rate | Fair value per unit (in dollars) |
|----------------------------|------------|--|---------------------------------------|----------------------------|----------------------|-------------------------|-------------------------|----------------------------------|
| Employee stock option plan | 2014.01.15 | \$ 27.5  | \$ 15.0                               | 48.22%                     | 10 years             | 0%                      | 1.09%                   | \$ 18.20                         |
| "                          | 2014.05.02 | 27.5   | 15.0                                  | 48.22%                     | 10 years             | 0%                      | 1.09%                   | 18.20                            |
| "                          | 2014.09.03 | 31.5   | 50.0                                  | 48.22%                     | 10 years             | 0%                      | 1.02%                   | 10.79                            |
| "                          | 2015.02.12 | 31.5   | 50.0                                  | 48.22%                     | 10 years             | 0%                      | 1.02%                   | 10.79                            |
| "                          | 2015.05.27 | 31.5   | 50.0                                  | 48.22%                     | 10 years             | 0%                      | 1.02%                   | 10.79                            |
| "                          | 2015.09.09 | 31.5   | 50.0                                  | 42.87%                     | 10 years             | 0%                      | 0.93%                   | 12.80                            |
| "                          | 2015.12.15 | 31.5   | 50.0                                  | 42.87%                     | 10 years             | 0%                      | 0.93%                   | 12.80                            |
| "                          | 2016.03.02 | 31.5   | 50.0                                  | 42.87%                     | 10 years             | 0%                      | 0.93%                   | 12.80                            |
| "                          | 2016.09.02 | 35.6   | 50.0                                  | 42.31%                     | 10 years             | 0%                      | 0.78%                   | 15.33                            |
| "                          | 2017.01.01 | 35.6   | 70.0                                  | 42.31%                     | 10 years             | 0%                      | 0.78%                   | 15.33                            |
| "                          | 2017.04.01 | 35.6   | 70.0                                  | 42.31%                     | 10 years             | 0%                      | 0.78%                   | 15.33                            |
| "                          | 2017.06.01 | 35.6   | 70.0                                  | 42.31%                     | 10 years             | 0%                      | 0.78%                   | 15.33                            |
| "                          | 2018.03.23 | 25.0   | 25.0                                  | 27.45%                     | 10 years             | 0%                      | 0.70%                   | 4.04                             |
| "                          | 2018.09.18 | 25.0   | 25.0                                  | 27.45%                     | 10 years             | 0%                      | 0.70%                   | 4.04                             |
| "                          | 2019.01.01 | 24.8   | 25.0                                  | 33.75%                     | 6.25 years           | 0%                      | 0.77%                   | 8.46                             |
| "                          | 2019.03.01 | 21.9   | 25.0                                  | 33.51%                     | 6.25 years           | 0%                      | 0.73%                   | 6.44                             |
| "                          | 2019.10.01 | 20.9   | 25.0                                  | 32.32%                     | 6.25 years           | 0%                      | 0.65%                   | 5.59                             |
| "                          | 2020.04.01 | 24.4   | 25.0                                  | 38.05%                     | 6.25 years           | 0%                      | 0.44%                   | 8.94                             |
| "                          | 2020.05.01 | 20.4   | 25.0                                  | 38.39%                     | 6.25 years           | 0%                      | 0.44%                   | 6.47                             |
| "                          | 2021.07.01 | 23.0   | 25.0                                  | 46.15%                     | 6.25 years           | 0%                      | 0.35%                   | 9.58                             |
| "                          | 2021.08.01 | 23.0   | 25.0                                  | 46.15%                     | 6.25 years           | 0%                      | 0.35%                   | 9.58                             |
| "                          | 2021.09.01 | 23.0   | 25.0                                  | 46.15%                     | 6.25 years           | 0%                      | 0.35%                   | 9.58                             |
| "                          | 2021.10.01 | 23.0   | 25.0                                  | 46.15%                     | 6.25 years           | 0%                      | 0.35%                   | 9.58                             |
| "                          | 2022.04.01 | 23.7   | 25.0                                  | 45.62%                     | 6.25 years           | 0%                      | 0.95%                   | 10.22                            |
| "                          | 2022.05.01 | 23.7   | 25.0                                  | 45.62%                     | 6.25 years           | 0%                      | 0.95%                   | 10.22                            |
| "                          | 2022.06.01 | 23.7   | 25.0                                  | 45.62%                     | 6.25 years           | 0%                      | 0.95%                   | 10.22                            |
| "                          | 2023.01.01 | 23.7   | 25.0                                  | 45.62%                     | 6.25 years           | 0%                      | 0.95%                   | 10.22                            |
| "                          | 2024.01.01 | 22.1   | 20.0                                  | 46.54%                     | 6.25 years           | 0%                      | 1.20%                   | 10.73                            |
| "                          | 2024.06.01 | 22.1   | 20.0                                  | 46.54%                     | 6.25 years           | 0%                      | 1.20%                   | 10.73                            |
| "                          | 2024.08.01 | 22.1   | 20.0                                  | 46.54%                     | 6.25 years           | 0%                      | 1.20%                   | 10.73                            |
| "                          | 2024.10.01 | 22.1   | 20.0                                  | 46.54%                     | 6.25 years           | 0%                      | 1.20%                   | 10.73                            |
| "                          | 2024.12.01 | 22.1   | 20.0                                  | 46.54%                     | 6.25 years           | 0%                      | 1.20%                   | 10.73                            |

Note: Expected price volatility rate was estimated by using the average price volatility of similar listed and OTC companies within the appropriate period.

(c) The employee stock option plan of subsidiary, Obigen Pharma, Inc.:

| Type of agreement          | Grant date | Underlying market value on measurement date (in dollars) | Exercise price per share (in dollars) | Expected volatility (Note) | Expected option life | Expected dividend yield | Risk-free interest rate | Fair value per unit (in dollars) |
|----------------------------|------------|--|---------------------------------------|----------------------------|----------------------|-------------------------|-------------------------|----------------------------------|
| Employee stock option plan | 2021.12.09 | \$ 20.7  | \$ 20.0                               | 47.29%                     | 6.375 years          | 0%                      | 0.49%                   | \$ 9.70                          |
| "                          | 2022.03.23 | 23.9   | 20.0                                  | 47.20%                     | 6.375 years          | 0%                      | 0.91%                   | 12.25                            |
| "                          | 2022.10.28 | 31.0   | 20.0                                  | 42.72%                     | 6.375 years          | 0%                      | 1.52%                   | 17.59                            |
| "                          | 2023.05.26 | 32.1   | 20.0                                  | 43.20%                     | 6.375 years          | 0%                      | 1.09%                   | 18.32                            |
| "                          | 2023.05.26 | 32.1   | 20.0                                  | 47.69%                     | 4.250 years          | 0%                      | 1.07%                   | 17.29                            |
| "                          | 2023.12.06 | 32.0   | 20.0                                  | 44.18%                     | 6.375 years          | 0%                      | 1.20%                   | 18.54                            |
| "                          | 2024.03.20 | 32.1   | 20.0                                  | 49.48%                     | 4.250 years          | 0%                      | 1.22%                   | 17.62                            |
| "                          | 2024.12.10 | 32.0   | 32.0                                  | 49.33%                     | 6.375 years          | 0%                      | 1.52%                   | 15.78                            |
| "                          | 2025.02.18 | 32.0   | 32.0                                  | 49.98%                     | 6.375 years          | 0%                      | 1.55%                   | 15.93                            |
| "                          | 2025.10.02 | 36.8   | 32.0                                  | 49.61%                     | 6.375 years          | 0%                      | 1.31%                   | 19.40                            |

Note: Expected price volatility rate was estimated by using the average price volatility of similar listed and OTC companies within the appropriate period.

- F. For the years ended December 31, 2025 and 2024, the Group recognised compensation cost of \$31,745 and \$63,743, respectively.
- G. For the years ended December 31, 2025 and 2024, the Group recognised compensation cost of \$2 and \$233, respectively, due to stock options issued by AP Biosciences, Inc. to the employees of the Company in prior years.
- H. On November 12, 2024, the Company adjusted the exercise prices of employee stock options issued between May 6, 2015 and August 2, 2024, in accordance with the employee stock option plan. The exercise price range was lowered from \$59.9 to \$575.3 to \$58.7 to \$509.7 (in dollars). This adjustment was made due to the issuance of new shares by the Company, and it did not result in any incremental fair value of the stock options.
- I. The Group conducted a capital reduction to cover accumulated deficit in 2025, and therefore adjusted the exercise price in accordance with the employee stock option plan.

(16) Share capital

A. As of December 31, 2025, the Company's authorized capital was \$5,000,000, consisting of 500 million shares of ordinary stock (including 40 million shares reserved for employee stock options), and the outstanding capital was \$1,315,797 with a par value of \$10 (in dollars) per share.

Movements in the number of the Company's ordinary shares outstanding are as follows:

(Unit: shares in thousands)

|  | 2025           | 2024           |
|--|----------------|----------------|
| At January 1                                     | 262,968        | 229,248        |
| Subsidiary's disposal of parent company's shares | 191            | -              |
| Capital reduction to cover accumulated deficit ( | 131,579)       | -              |
| Cash capital increase                            | -              | 33,800         |
| Cancellation of employee restricted stocks       | -              | ( 80)          |
| At December 31                                   | <u>131,580</u> | <u>262,968</u> |

- B. The Board of Directors during its meeting on August 8, 2022 adopted a resolution to issue employee restricted ordinary shares with the effective date set on October 25, 2022. The number of shares issued is 160 thousand shares with a par value of NT\$10 (in dollars) per share. On December 10, 2024, the Board of Directors resolved to cancel 80 thousand shares, with the record date of reduction set on December 10, 2024.
- C. On September 1, 2025, the Company's Board of Directors resolved to cover accumulated deficit through a capital reduction, decreasing capital by \$1,315,797 and cancelling 131,579 thousand issued common shares, with a capital reduction ratio of 50%. This capital reduction plan was resolved at the extraordinary shareholders' meeting on October 20, 2025, with the capital reduction record date set as November 24, 2025.
- D. The Company conducted a cash capital increase by issuing 33,800 thousand new shares with a par value of \$10 (in dollars) per share. The capital increase record date was set on November 12, 2024.

E. Treasury stock:

- (a) Reason for share reacquisition and movements in the number of the Company's treasury shares are as follows:

| Reason for reacquisition  | Year ended December 31, 2025 |           |                           |                           | Carrying amount (Note 2) |
|---|------------------------------|-----------|---------------------------|---------------------------|--------------------------|
|   | Beginning shares             | Additions | Disposal                  | Ending shares             |                          |
| Shares of the parent company held by subsidiaries treated as treasury shares (Note 1) | 191<br>thousand<br>shares    | -         | 191<br>thousand<br>shares | -                         | \$ -                     |
| Reason for reacquisition  | Year ended December 31, 2024 |           |                           |                           | Carrying amount          |
|   | Beginning shares             | Additions | Disposal                  | Ending shares             |                          |
| Shares of the parent company held by subsidiaries treated as treasury shares (Note 1) | 191<br>thousand<br>shares    | -         | -                         | 191<br>thousand<br>shares | \$ 26,533                |

Note 1: Shares of the parent company held by subsidiaries are treated as treasury shares but are entitled to the shareholders' rights. The number of shares was calculated by multiplying the number of shares of the Company held by the subsidiaries by the Company's shareholding ratio to subsidiaries.

Note 2: Shares of the parent company held by subsidiaries, Amaran Biotechnology Inc. were sold in 2025, reducing the carrying amount of treasury stock to \$0.

- (b) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury share should not exceed 10% of the number of the Company's issued and outstanding shares and the amount bought back should not exceed the sum of retained earnings, paid-in capital in excess of par value and realised capital surplus.
- (c) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares should not be pledged as collateral and is not entitled to dividends before it is reissued.

(17) Capital surplus

Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

|   | 2025                |                        |                   |                     |
|---|---------------------|------------------------|-------------------|---------------------|
|   | Share premium       | Employee stock options | Restricted stocks | Others              |
| At January 1  | \$ 6,896,039        | \$ 731,257             | \$ 4,480          | \$ 1,468,965        |
| Employee stock option compensation cost   | -                   | 11,243                 | -                 | 2,129               |
| Vesting of restricted employee stocks   | 2,569               | -                      | ( 2,569)          | -                   |
| Subsidiary employees exercising stock options   | -                   | -                      | -                 | 267                 |
| Expiration of employee stock options  | -                   | ( 214,672)             | -                 | 223,211             |
| Changes in associates accounted for using equity method                                   | -                   | -                      | -                 | 3,380               |
| Difference between consideration and carrying amount of subsidiaries acquired or disposed | -                   | -                      | -                 | 99,683              |
| Treasury stock transactions   | -                   | -                      | -                 | ( 21,612)           |
| At December 31  | <u>\$ 6,898,608</u> | <u>\$ 527,828</u>      | <u>\$ 1,911</u>   | <u>\$ 1,776,023</u> |

|   | 2024                |                        |                   |                     |
|---|---------------------|------------------------|-------------------|---------------------|
|   | Share premium       | Employee stock options | Restricted stocks | Others              |
| At January 1  | \$ 5,065,714        | \$ 834,682             | \$ 8,960          | \$ 1,218,394        |
| Cash capital increase                                   | 1,825,200           | -                      | -                 | -                   |
| Cancellation of restricted employee stocks              | -                   | -                      | ( 4,480)          | -                   |
| Employee stock options compensation cost                | 5,125               | 22,272                 | -                 | 9,238               |
| Expiration of employee stock options                    | -                   | ( 125,697)             | -                 | 129,378             |
| Changes in associates accounted for using equity method | -                   | -                      | -                 | 111,955             |
| At December 31  | <u>\$ 6,896,039</u> | <u>\$ 731,257</u>      | <u>\$ 4,480</u>   | <u>\$ 1,468,965</u> |

(18) Retained earnings

- A. The current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses and then 10% of the remaining amount shall be set aside as legal reserve. Cash dividends shall first be appropriated, and the remainder, if any, to be retained or to be appropriated shall be resolved by the stockholders at the stockholders' meeting.

- B. The Company is facing a capital intensive industrial environment, with the life cycle of the industry in the growth phase. The residual dividend policy is adopted taking into consideration the Company's operating expansion plans and investment demands. According to the balanced dividend policy adopted by the Board of Directors, stock dividends and cash dividends will be allocated in consideration of the actual net income and funds status and are subject to the approval by the Board of Directors and resolution by shareholders and cash dividends shall account for at least 10% of the total dividends distributed.
- C. Except for covering accumulated deficit, increasing capital or payment of cash, the legal reserve shall not be used for any other purpose. The amount capitalised or the cash payment shall not exceed 25% of the paid-in capital.
- D. As resolved by the shareholders on June 27, 2025, the Company's proposal for 2024 deficit compensation is as follows:

|  | Year ended<br>December 31, 2024 |
|--|---------------------------------|
| Accumulated deficit at beginning of the year | (\$ 5,569,013)                  |
| Net loss for 2024                            | ( 2,310,026)                    |
| Accumulated deficit at end of the year       | (\$ 7,879,039)                  |

- E. As resolved by the shareholders on March 9, 2026, the Company's proposal for 2025 deficit compensation is as follows:

|  | Year ended<br>December 31, 2025 |
|--|---------------------------------|
| Accumulated deficit at beginning of the year   | (\$ 7,879,039)                  |
| Capital reduction to cover accumulated deficit | 1,315,797                       |
| Net loss for 2025                              | ( 2,052,823)                    |
| Accumulated deficit at end of the year         | (\$ 8,616,065)                  |

As of March 9, 2026, the aforementioned proposal for 2025 deficit compensation has not yet been resolved by the shareholders. Details are provided in Note 6 (13)C.

(19) Operating revenue

Disaggregation of revenue from contracts with customers is as follows:

|                                       | Years ended December 31, |           |
|---------------------------------------|--------------------------|-----------|
|                                       | 2025                     | 2024      |
| Revenue from contracts with customers | \$ 58,575                | \$ 62,678 |

Disaggregation of revenue from contracts with customers is as follows:

| Year ended<br>December 31, 2025          | Contract<br>Development<br>and Manufacturing<br>Organization revenue | Patent Technology<br>Licensing | Total     |
|--|--|--------------------------------|-----------|
| Revenue from external customer contracts |  |                                |           |
| Contract revenue                         | \$ 50,007  | \$ 8,568                       | \$ 58,575 |

| Year ended<br>December 31, 2024          | Contract<br>Development<br>and Manufacturing<br>Organization revenue | Patent Technology<br>Licensing | Total     |
|--|--|--------------------------------|-----------|
| Revenue from external customer contracts |  |                                |           |
| Contract revenue                         | \$ 60,795  | \$ 1,883                       | \$ 62,678 |

The Group has recognised the following revenue-related contract assets:

|                                   | December 31, 2025 | December 31, 2024 | January 1, 2024 |
|-----------------------------------|-------------------|-------------------|-----------------|
| Contract assets                   |                   |                   |                 |
| Contract assets – service revenue | \$ 2,414          | \$ -              | \$ -            |

The Group has recognised the following revenue-related contract liabilities:

|   | December 31, 2025 | December 31, 2024 | January 1, 2024 |
|---|-------------------|-------------------|-----------------|
| Contract liabilities                    |                   |                   |                 |
| Contract liabilities – unearned revenue | \$ 2,293          | \$ 7,783          | \$ 6,285        |

For the years ended December 31, 2025 and 2024, the Group recognised revenues from the beginning balance of contract liabilities amounting to \$5,643, and \$2,840, respectively.

(20) Interest income

|  | Years ended December 31, |           |
|--|--------------------------|-----------|
|  | 2025                     | 2024      |
| Interest income from bank deposits                               | \$ 12,354                | \$ 23,374 |
| Interest income from financial assets measured at amortised cost | 17,440                   | 16,697    |
|  | \$ 29,794                | \$ 40,071 |

(21) Other income

|                             | Years ended December 31, |                  |
|-----------------------------|--------------------------|------------------|
|                             | 2025                     | 2024             |
| Rent income                 | \$ 350                   | \$ 350           |
| Other income, others (Note) | 47,643                   | 12,770           |
|                             | <u>\$ 47,993</u>         | <u>\$ 13,120</u> |

Note: Due to the termination of the research and development projects, the Group settled accounts with the contracted research organization (CRO) and have its project funds returned.

(22) Other gains and losses

|   | Years ended December 31, |                  |
|---|--------------------------|------------------|
|   | 2025                     | 2024             |
| Gain on disposal of intangible assets (Note)                        | \$ 45,000                | \$ -             |
| (Losses) gains on disposal of property, plant and equipment         | ( 122)                   | 43,720           |
| Gains on disposals of investments                                   | -                        | 397              |
| Net currency exchange gains   | 4,891                    | 25,442           |
| Net losses on financial assets at fair value through profit or loss | ( 89)                    | ( 138)           |
| Losses on lease modification  | ( 3,001)                 | -                |
| Others  | ( 34)                    | ( 3,464)         |
|   | <u>\$ 46,645</u>         | <u>\$ 65,957</u> |

Note: The Group sold the patent rights of CRM197 diphtheria toxin (carrier protein of OBI-833).

(23) Finance costs

|                                       | Years ended December 31, |                  |
|---------------------------------------|--------------------------|------------------|
|                                       | 2025                     | 2024             |
| Interest expense                      |                          |                  |
| Interest expense on lease liabilities | \$ 8,505                 | \$ 9,594         |
| Interest expense on loans             | 4,628                    | 1,057            |
|                                       | <u>\$ 13,133</u>         | <u>\$ 10,651</u> |

(24) Expenses by nature

|                              | Years ended December 31, |                     |
|------------------------------|--------------------------|---------------------|
|                              | 2025                     | 2024                |
| Clinical trials cost         | \$ 674,405               | \$ 631,744          |
| Employee benefit expenses    | 561,431                  | 598,043             |
| Clinical material expenses   | 276,793                  | 414,971             |
| Depreciation                 | 206,783                  | 203,403             |
| Consulting and service fees  | 181,541                  | 128,560             |
| Outsourced research expenses | 119,244                  | 135,674             |
| Amortisation                 | 20,379                   | 18,851              |
| Rental expenses              | 3,323                    | 4,809               |
| Royalty fees                 | -                        | 94,260              |
| Other expenses               | 183,462                  | 203,891             |
| Operating costs and expenses | <u>\$ 2,227,361</u>      | <u>\$ 2,434,206</u> |

(25) Employee benefit expense

|  | Years ended December 31, |                   |
|--|--------------------------|-------------------|
|  | 2025                     | 2024              |
| Wages and salaries (including directors' remuneration) | \$ 452,864               | \$ 454,937        |
| Share-based payment expense                            | 31,747                   | 63,976            |
| Labor and health insurance fees                        | 25,037                   | 25,574            |
| Pension costs  | 18,823                   | 19,492            |
| Other personnel expenses                               | 32,960                   | 34,064            |
|  | <u>\$ 561,431</u>        | <u>\$ 598,043</u> |

A. In accordance with the Articles of Incorporation, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall not be lower than 2% for employees' compensation (of which 10% shall be reserved for its non-executive employees) and shall not be higher than 2% for directors' remuneration. A company may, by a resolution adopted by a majority vote at a meeting of Board of Directors attended by two-thirds of the total number of directors, have the abovementioned employees' compensation distributed in the form of shares or in cash; and in addition thereto a report of such distribution shall be submitted to the shareholders during their meeting. Qualification requirements of employees, including the employees of subsidiaries of the company meeting certain specific requirements, entitled to receive aforementioned stock or cash may be specified in the Articles of Incorporation. The term shall be defined by the Board of Directors.

B. As of December 31, 2025 and 2024, the Company had an accumulated deficit; thus, no employees' compensation and directors' remuneration was recognised nor distributed for the years ended December 31, 2025 and 2024.

C. As of December 31, 2024, the Company had an accumulated deficit; thus, no employees' compensation and directors' remuneration were distributed, which were in agreement with the amount recognised in the 2024 financial statements. Information about employees' compensation and directors' remuneration of the Company as resolved by the shareholders will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(26) Income tax

A. Components of income tax benefit:

|                                      | Years ended December 31, |            |
|--------------------------------------|--------------------------|------------|
|                                      | 2025                     | 2024       |
| Current tax:                         |                          |            |
| Current tax on loss for the year     | \$ 11,218                | \$ 16,373  |
| Prior year income tax overestimation | ( 13,944)                | ( 19,935)  |
| Total current tax                    | (\$ 2,726)               | (\$ 3,562) |

For the years ended December 31, 2025 and 2024, there was no deferred income tax incurred.

B. The reconciliation between accounting income and income tax benefit:

|   | Years ended December 31, |              |
|---|--------------------------|--------------|
|   | 2025                     | 2024         |
| Tax calculated based on loss before tax and statutory tax rate            | (\$ 399,334)             | (\$ 452,076) |
| Tax effects of items required to be added by tax regulation               | 42,935                   | 24,711       |
| Tax effects of items disallowed by tax regulation                         | 120                      | 100          |
| Tax effects of items required to be separately computed by tax regulation | -                        | ( 8,055)     |
| House and land transactions income tax                                    | -                        | 8,055        |
| Tax effects of unrecognised deferred tax assets                           | 367,497                  | 443,638      |
| Prior year income tax overestimation                                      | ( 13,944)                | ( 19,935)    |
| Income tax benefit  | (\$ 2,726)               | (\$ 3,562)   |

C. Details of the amount the Company and its subsidiary, Obigen Pharma, Inc., are entitled as investment tax credits and unrecognised deferred tax assets under the Act for the Development of Biotech and Pharmaceutical Industry are as follows:

(a) Amounts of investment tax credits and unrecognised deferred tax assets that the Company is entitled to are as follows:

| December 31, 2025                          |               |                                  |             |
|--|---------------|----------------------------------|-------------|
| Qualifying items                           | Unused amount | Unrecognised deferred tax assets | Expiry year |
| Research and development expense (Biotech) | \$ 1,469,112  | \$ 1,469,112                     | Note        |

| December 31, 2024                          |               |                                  |             |
|--|---------------|----------------------------------|-------------|
| Qualifying items                           | Unused amount | Unrecognised deferred tax assets | Expiry year |
| Research and development expense (Biotech) | \$ 1,335,697  | \$ 1,335,697                     | Note        |

(b) Amounts of investment tax credits and unrecognised deferred tax assets that the subsidiary, Obigen Pharma, Inc., is entitled to are as follows:

| December 31, 2025                          |               |                                  |             |
|--|---------------|----------------------------------|-------------|
| Qualifying items                           | Unused amount | Unrecognised deferred tax assets | Expiry year |
| Research and development expense (Biotech) | \$ 104,045    | \$ 104,045                       | Note        |

| December 31, 2024                          |               |                                  |             |
|--|---------------|----------------------------------|-------------|
| Qualifying items                           | Unused amount | Unrecognised deferred tax assets | Expiry year |
| Research and development expense (Biotech) | \$ 65,804     | \$ 65,804                        | Note        |

Note : The unused tax credits can be offset against the current income tax payable for the next five years with a range of not more than 50% of each year's income tax payable, but the last year can be fully offset.

D. Expiration dates of unused tax losses and amounts of unrecognised deferred tax assets for the Company and the subsidiaries are as follows:

(a) The Company

December 31, 2025

| Year incurred | Amount filed/<br>assessed | Unused<br>amount | Unrecognised<br>deferred tax<br>assets | Expiry year |
|---------------|---------------------------|------------------|--|-------------|
| 2016          | \$ 943,536                | \$ 943,536       | \$ 943,536                             | 2026        |
| 2017          | 1,040,320                 | 1,040,320        | 1,040,320                              | 2027        |
| 2018          | 1,211,688                 | 1,211,688        | 1,211,688                              | 2028        |
| 2019          | 1,186,227                 | 1,186,227        | 1,186,227                              | 2029        |
| 2020          | 1,106,846                 | 1,106,846        | 1,106,846                              | 2030        |
| 2021          | 194,682                   | 194,682          | 194,682                                | 2031        |
| 2022          | 1,286,041                 | 1,286,041        | 1,286,041                              | 2032        |
| 2023          | 1,318,044                 | 1,318,044        | 1,318,044                              | 2033        |
| 2024          | 1,834,659                 | 1,834,659        | 1,834,659                              | 2034        |
| 2025          | 1,330,547                 | 1,330,547        | 1,330,547                              | 2035        |

December 31, 2024

| Year incurred | Amount filed/<br>assessed | Unused<br>amount | Unrecognised<br>deferred tax<br>assets | Expiry year |
|---------------|---------------------------|------------------|--|-------------|
| 2015          | \$ 981,510                | \$ 981,510       | \$ 981,510                             | 2025        |
| 2016          | 943,536                   | 943,536          | 943,536                                | 2026        |
| 2017          | 1,040,320                 | 1,040,320        | 1,040,320                              | 2027        |
| 2018          | 1,211,688                 | 1,211,688        | 1,211,688                              | 2028        |
| 2019          | 1,186,227                 | 1,186,227        | 1,186,227                              | 2029        |
| 2020          | 1,106,846                 | 1,106,846        | 1,106,846                              | 2030        |
| 2021          | 194,682                   | 194,682          | 194,682                                | 2031        |
| 2022          | 1,286,041                 | 1,286,041        | 1,286,041                              | 2032        |
| 2023          | 1,318,044                 | 1,318,044        | 1,318,044                              | 2033        |
| 2024          | 1,834,659                 | 1,834,659        | 1,834,659                              | 2034        |

(b) The subsidiary, Amaran Biotechnology Inc.,

December 31, 2025

| Year incurred | Amount filed/<br>assessed | Unused<br>amount | Unrecognised<br>deferred tax<br>assets | Expiry year |
|---------------|---------------------------|------------------|--|-------------|
| 2016          | \$ 82,758                 | \$ 82,758        | \$ 82,758                              | 2026        |
| 2017          | 119,168                   | 119,168          | 119,168                                | 2027        |
| 2018          | 143,583                   | 143,583          | 143,583                                | 2028        |
| 2019          | 125,177                   | 125,177          | 125,177                                | 2029        |
| 2020          | 113,522                   | 113,522          | 113,522                                | 2030        |
| 2021          | 114,486                   | 114,486          | 114,486                                | 2031        |
| 2022          | 130,306                   | 130,306          | 130,306                                | 2032        |
| 2023          | 135,246                   | 135,246          | 135,246                                | 2033        |
| 2024          | 140,283                   | 140,283          | 140,283                                | 2034        |
| 2025          | 140,787                   | 140,787          | 140,787                                | 2035        |

December 31, 2024

| Year incurred | Amount filed/<br>assessed | Unused<br>amount | Unrecognised<br>deferred tax<br>assets | Expiry year |
|---------------|---------------------------|------------------|--|-------------|
| 2015          | \$ 70,767                 | \$ 70,767        | \$ 70,767                              | 2025        |
| 2016          | 82,758                    | 82,758           | 82,758                                 | 2026        |
| 2017          | 119,168                   | 119,168          | 119,168                                | 2027        |
| 2018          | 143,583                   | 143,583          | 143,583                                | 2028        |
| 2019          | 125,177                   | 125,177          | 125,177                                | 2029        |
| 2020          | 113,522                   | 113,522          | 113,522                                | 2030        |
| 2021          | 114,486                   | 114,486          | 114,486                                | 2031        |
| 2022          | 130,306                   | 130,306          | 130,306                                | 2032        |
| 2023          | 135,246                   | 135,246          | 135,246                                | 2033        |
| 2024          | 140,283                   | 140,283          | 140,283                                | 2034        |

(d) The subsidiary, Obigen Pharma, Inc.,

December 31, 2025

| Year incurred | Amount filed/<br>assessed | Unused<br>amount | Unrecognised<br>deferred tax<br>assets | Expiry year |
|---------------|---------------------------|------------------|--|-------------|
| 2021          | \$ 134,058                | \$ 134,058       | \$ 134,058                             | 2031        |
| 2022          | 216,422                   | 216,422          | 216,422                                | 2032        |
| 2023          | 245,452                   | 245,452          | 245,452                                | 2033        |
| 2024          | 274,003                   | 274,003          | 274,003                                | 2034        |
| 2025          | 326,855                   | 326,855          | 326,855                                | 2035        |

December 31, 2024

| <u>Year incurred</u> | <u>Amount filed/<br/>assessed</u> | <u>Unused<br/>amount</u> | <u>Unrecognised<br/>deferred tax<br/>assets</u> | <u>Expiry year</u> |
|----------------------|-----------------------------------|--------------------------|---|--------------------|
| 2021                 | \$ 134,058                        | \$ 134,058               | \$ 134,058                                      | 2031               |
| 2022                 | 216,422                           | 216,422                  | 216,422   | 2032               |
| 2023                 | 245,452                           | 245,452                  | 245,452   | 2033               |
| 2024                 | 274,003                           | 274,003                  | 274,003   | 2034               |

E. The income tax returns of OBI Pharma, Inc., Obigen Pharma, Inc. and Amaran Biotechnology Inc., through 2023 have been assessed and approved by the Tax Authority.

F. The subsidiary, OBI Pharma Australia Pty Ltd., was qualified for the Research and Development Tax Incentive provided by the Australian Government, and the subsidiary received prior year income tax refund amounting to \$14,006 and \$19,935 in 2025 and 2024, respectively.

(27) Loss per share

|   | <u>Year ended December 31, 2025</u> |   |  |
|---|-------------------------------------|---|--|
|   | <u>Amount after tax</u>             | <u>Weighted-average<br/>number of ordinary<br/>shares outstanding<br/>(shares in thousands)</u> | <u>Loss per share<br/>(in dollars)</u> |
| <u>Basic and diluted loss</u><br><u>per share</u><br>Loss attributable to<br>ordinary shareholders<br>of the parent | (\$ 2,052,823)                      | 131,479   | (\$ 15.61)                             |
|   | <u>Year ended December 31, 2024</u> |   |  |
|   | <u>Amount after tax</u>             | <u>Weighted-average<br/>number of ordinary<br/>shares outstanding<br/>(shares in thousands)</u> | <u>Loss per share<br/>(in dollars)</u> |
| <u>Basic and diluted loss</u><br><u>per share</u><br>Loss attributable to<br>ordinary shareholders<br>of the parent | (\$ 2,310,026)                      | 116,807   | (\$ 19.78)                             |

Note 1: The potential ordinary shares have anti-dilutive effect due to net loss for the years ended December 31, 2025 and 2024, so the calculation of diluted loss per share is the same as the calculation of basic loss per share.

Note 2: The Company completed a capital reduction to cover accumulated deficit in 2025; therefore, the weighted average number of outstanding shares was retrospectively adjusted.

(28) Non-controlling interest

- A. For the years ended December 31, 2025 and 2024, the Group's subsidiaries, Amaran Biotechnology Inc. and Obigen Pharma, Inc., recognised employee compensation cost for the Company's or each subsidiaries' employee stock options granted to their respective employees as well as the expiration of certain stock options. Further, some subsidiaries granted their employee stock options to the Company's employees. These resulted to an increase in the non-controlling interest by \$9,147 and \$24,055, respectively, and an increase in equity attributable to owners of the parent by \$8,605 and \$3,890, respectively.
- B. For the year ended December 31, 2025, the subsidiary's, Amaran Biotechnology Inc.'s, employees exercised stock options, resulting to an increase in the non-controlling interest by \$20,638 and equity attributable to owners of the parent by \$267. There was no such transaction for the year ended December 31, 2024.
- C. Due to the conversion of employee stock options into common shares, the subsidiary, Obigen Pharma, Inc. had collected capital in advance amounting to \$1,055 as of December 31, 2025, resulting in an increase of \$1,055 in non-controlling interests. There was no such transaction for the year ended December 31, 2024.
- D. In 2025, the Group disposed of partial ownership interests in the subsidiary, Obigen Pharma, Inc., resulting in an increase in non-controlling interests and equity attributable to the parent company by \$3,058 and \$99,683, respectively. There was no such transaction in 2024.
- E. The subsidiary, Amaran Biotechnology Inc., disposed of the Company's shares in 2025, resulting in an increase of \$2,033 in non-controlling interests. There was no such transaction in 2024.
- F. The changes in non-controlling interests in the subsidiaries, Amaran Biotechnology Inc. and Obigen Pharma, Inc., and the effects on the equity attributable to owners of the parent for the years ended December 31, 2025 and 2024 are shown below:

Effect of changes in subsidiary ownership equity:

|  | Years ended December 31, |      |
|--|--------------------------|------|
|  | 2025                     | 2024 |
| Cash   | \$ 20,905                | \$ - |
| Increase in the carrying amount of non-controlling interest                    | ( 20,638)                | -    |
| Capital surplus - recognition of changes in ownership interest in subsidiaries | \$ 267                   | \$ - |

Effect of disposal of ownership interests in subsidiaries (without losing control):

|   | Years ended December 31, |      |
|---|--------------------------|------|
|   | 2025                     | 2024 |
| Cash  | \$ 102,741               | \$ - |
| Increase in the carrying amount of non-controlling interest   | ( 3,058)                 | -    |
| Capital surplus – difference between consideration and carrying amount of subsidiaries acquired or disposed | \$ 99,683                | \$ - |

Effect of share-based payment transactions:

|   | Years ended December 31, |           |
|---|--------------------------|-----------|
|   | 2025                     | 2024      |
| Employee compensation cost                                  | \$ 17,752                | \$ 27,945 |
| Increase in the carrying amount of non-controlling interest | ( 9,147)                 | ( 24,055) |
| Capital surplus - others                                    | \$ 8,605                 | \$ 3,890  |

Effect of shares of the Company held by subsidiary treated as treasury shares:

|   | Years ended December 31, |      |
|---|--------------------------|------|
|   | 2025                     | 2024 |
| Recognised as treasury shares                           | \$ 6,954                 | \$ - |
| Increase in carrying amount of non-controlling interest | ( 2,033)                 | -    |
| Treasury shares   | ( 26,533)                | -    |
| Capital surplus – others                                | (\$ 21,612)              | \$ - |

(29) Supplemental cash flow information

A. Investing activities with partial cash payments:

|  | Years ended December 31, |            |
|--|--------------------------|------------|
|  | 2025                     | 2024       |
| Acquisition of property, plant and equipment | \$ 37,340                | \$ 115,877 |
| Add: Opening balance of payable              | 8,490                    | 3,834      |
| Less: Ending balance of payable              | ( 2,869)                 | ( 8,490)   |
| Cash paid during the year                    | \$ 42,961                | \$ 111,221 |

- B. On May 10, 2024, the Board of Directors of the Company resolved to terminate the exclusive licensing agreement in China (including Hong Kong and Macao) of OBI-833 (Globo H Adagloxad Simolenin) and OBI-999 (Globo H Antibody Drug Conjugate) entered into by the Company and Odeon Therapeutics (Hong Kong) Limited on February 22, 2022. Additionally,

the Company signed a contract with Odeon Therapeutics (Hong Kong) Limited on the same day. Consequently, the Group lost its control over Odeon (refer to Note 4(3)). The information of the company's related assets and liabilities is as follows:

|  | <u>May 10, 2024</u> |
|--|---------------------|
| Carrying amount of the assets and liabilities of Odeon                   |                     |
| Cash and cash equivalents  | \$ 30,414           |
| Other receivables  | 450                 |
| Other payables   | ( 449)              |
| Financial liabilities at fair value through profit or loss - non-current | ( 48,623)           |
| Total net assets   | <u>(\$ 18,208)</u>  |

(30) Changes in liabilities from financing activities

|  | <u>Lease liabilities</u> | <u>Short-term borrowings</u> | <u>Long-term borrowings</u> | <u>Liabilities from financing activities - gross</u> |
|--|--------------------------|------------------------------|-----------------------------|--|
| At January 1, 2025                             | \$ 421,903               | \$ 412                       | \$ 82,311                   | \$ 504,626   |
| Changes in cash flow from financing activities | ( 57,927)                | 49,941                       | 19,017                      | 11,031   |
| Impact of changes in foreign exchange rate     | ( 279)                   | -                            | -                           | ( 279)   |
| Others   | 299                      | -                            | -                           | 299  |
| At December 31, 2025                           | <u>\$ 363,996</u>        | <u>\$ 50,353</u>             | <u>\$ 101,328</u>           | <u>\$ 515,677</u>                                    |

|  | <u>Lease liabilities</u> | <u>Short-term borrowings</u> | <u>Long-term borrowings</u> | <u>Guarantee deposits received</u> | <u>Liabilities from financing activities - gross</u> |
|--|--------------------------|------------------------------|-----------------------------|------------------------------------|--|
| At January 1, 2024                             | \$ 475,748               | \$ 4,305                     | \$ 21,000                   | \$ 3                               | \$ 501,056   |
| Changes in cash flow from financing activities | ( 45,746)                | ( 3,893)                     | 61,311                      | ( 3)                               | 11,669   |
| Impact of changes in foreign exchange rate     | 446                      | -                            | -                           | -                                  | 446  |
| Others   | ( 8,545)                 | -                            | -                           | -                                  | ( 8,545)   |
| At December 31, 2024                           | <u>\$ 421,903</u>        | <u>\$ 412</u>                | <u>\$ 82,311</u>            | <u>\$ -</u>                        | <u>\$ 504,626</u>                                    |

7. RELATED PARTY TRANSACTIONS

(1) Name of related parties and relationship

| <u>Name of related party</u> | <u>Relationship with the Group</u>         |
|------------------------------|--|
| AP Biosciences, Inc.         | Investee accounted for using equity method |

(2) Significant related party transactions

A. Operating revenue

|  | Years ended December 31, |      |
|--|--------------------------|------|
|  | 2025                     | 2024 |
| Service revenue                            |                          |      |
| Investee accounted for using equity method |                          |      |
| -AP Biosciences, Inc.                      | \$ 808                   | \$ - |

AP Biosciences, Inc. commissioned the Group to execute a research and development project. The price and payment terms were based on mutual agreement.

B. Non-operating income

|  | Years ended December 31, |       |
|--|--------------------------|-------|
|  | 2025                     | 2024  |
| Other income                               |                          |       |
| Investee accounted for using equity method |                          |       |
| -AP Biosciences, Inc.                      | \$ 11                    | \$ 34 |

The Group offered AP Biosciences, Inc. to use as trial equipment. The price and payment terms were based on mutual agreement.

C. Research and development expenses

|  | Years ended December 31, |        |
|--|--------------------------|--------|
|  | 2025                     | 2024   |
| Investee accounted for using equity method |                          |        |
| -AP Biosciences, Inc.                      | \$ 84                    | \$ 178 |

The Group used testing instruments of AP Biosciences, Inc., and the prices and payment terms were based on mutual agreement.

(3) Key management compensation

|   | Years ended December 31, |                   |
|---|--------------------------|-------------------|
|   | 2025                     | 2024              |
| Salaries and other short-term employee benefits | \$ 163,006               | \$ 175,772        |
| Share-based payments                            | 12,496                   | 22,894            |
|   | <u>\$ 175,502</u>        | <u>\$ 198,666</u> |

## 8. PLEGGED ASSETS

The Group's assets pledged as collateral are as follows:

| Pledged asset                                    | Book value           |                      | Purpose  |
|--|----------------------|----------------------|--|
|  | December 31,<br>2025 | December 31,<br>2024 |  |
| Financial assets at amortised cost - non-current | \$ 16,400            | \$ 12,900            | Duty paid after customer release and factory deposits.   |
| Buildings and structures                         | 203,585              | 219,488              | Short-term borrowings and long-term borrowings (Note 1)  |
| Machinery and equipment                          | 88,901               | -                    | Long-term borrowings (Note 2)  |
| Other non-current assets (refundable deposits)   | 35,373               | 24,119               | Deposits for clinical trial agreement, rental deposit, letters of credit, and long-term borrowings, etc.(Note 2) |
|  | <u>\$ 344,259</u>    | <u>\$ 256,507</u>    |  |

Note 1: The subsidiary, Amaran Biotechnology Inc., entered into a loan agreement with Mega International Commercial Bank as of December 31, 2025 and 2024, for a total credit facility of \$100 million, and pledged properties as collateral with line of credit guarantee to Mega International Commercial Bank. Refer to Notes 6(10) and 6(11) for details.

Note 2: The subsidiary, Amaran Biotechnology Inc., entered into a loan agreement with Chailease Specialty Finance Co., Ltd. in 2025 for a total credit facility of \$75,000, with guarantee deposits paid and machinery and equipment pledged as collateral. Refer to Note 6(11) for details for loans.

## 9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

Aside from the commitments described in Note 6(9), others are as follows:

(1) The Company purchased patent named "OBI-822" (formerly named "OPT-822"), therapeutically metastatic breast cancer vaccines on December 29, 2003. The amount of payment was determined based on whether the milestones in the agreement are achieved or not. As of December 31, 2025, the remaining unpaid amount was US\$9 million. The Company decided to terminate the Phase III clinical trial of OBI-822 for triple-negative breast cancer in April 2025. Given that the payment under the contract is conditional upon achievement of certain milestones, the Company management is of the opinion that the Company has no obligation to settle the aforementioned unpaid amount in the short term. Refer to Note 6(13) for details.

(2) Pursuant to the government grants for OBI-822, therapeutically metastatic breast cancer vaccines, in Phase II obtained by the Company from Department of Industrial Technology of Ministry of Economic Affairs R.O.C. (MOEA) on December 25, 2012, if OBI-822 will be successfully licensed to others, the Company promises to contribute 5% of the signing bonus and achieved milestones as feedback fund and the maximum amount for feedback fund is \$150,256. The Company decided to terminate the Phase III clinical trial of OBI-822 for triple-negative breast cancer in April 2025. Given that the payment under the contract is conditional upon achievement of certain milestones, the

Company management is of the opinion that the Company has no obligation to settle the aforementioned unpaid amount in the short term. Refer to Note 6(13) for details.

- (3) The Company entered into a licensing agreement of ‘Nectin-4 humanised antibody sequences’ with Ablexis, LLC on July 3, 2023. The amount of payment was determined based on whether the milestones in the agreement were achieved or not. As of December 31, 2025, the remaining unpaid amount was US\$8,570 thousand.
- (4) To conduct clinical trials of new drugs research, the Group entered into outsourcing research agreements with a variety of CROs (Contract research organizations). Service fees and other miscellaneous expenses are calculated based on the number of patients accepted in the clinical trials, and becomes billable pursuant to the progress of the clinical trials. The agreements can be terminated at any time.
- (5) The Group had a dispute with Biosion, Inc. regarding the rights to the research, development, and commercialization of Trop2 ADC, and filed for rapid arbitration in Delaware, USA, in 2025 in accordance with the contract provisions. The Group assessed that there is no significant adverse impact on its business and financial condition.

#### 10. SIGNIFICANT DISASTER LOSS

None.

#### 11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

Refer to Note 6(18) for details on the proposal for 2025 deficit compensation.

#### 12. OTHERS

##### (1) Capital management

The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern through maintaining an optimal capital structure to reduce the cost of capital, and to provide returns for shareholders after the Company turns around from loss to profit. In order maintain or adjust the capital structure, the Group may increase capital by cash and sell assets to pay off or improve operating capital, adjust the amount of dividends paid to shareholders or capital reduction, etc. The Group monitors capital on the basis of the Debt/Equity ratio. The ratio is calculated by the “Net debt” divided by the “Total equity”. The “Net debt” is the “Total liability” less cash and cash equivalents, and the “Total equity” is the same as the consolidated balance sheet. During 2025, the Group’s strategy, which was unchanged from 2024, was to maintain the gearing ratio within reasonable security range. The ratios are as follows:

|                                 | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|---------------------------------|--------------------------|--------------------------|
| Total liability                 | \$ 696,131               | \$ 833,385               |
| Less: Cash and cash equivalents | ( 759,330)               | ( 1,732,050)             |
| Net debt (Note)                 | (\$ 63,199)              | (\$ 898,665)             |
| Total equity                    | <u>\$ 2,725,134</u>      | <u>\$ 4,820,307</u>      |

Note: The Group places funds that are not expected to be used in the short term in time deposits exceeding three months with domestic financial institutions. As of December 31, 2025 and 2024, the Group's cash and cash equivalents and time deposits over three months amounted to \$1,186,330 and \$3,130,750 respectively, which are sufficient to cover the Group's liabilities.

(2) Financial instruments

A. Financial instruments by category

|   | <u>December 31, 2025</u> | <u>December 31, 2024</u> |
|---|--------------------------|--------------------------|
| <u>Financial assets</u>   |                          |                          |
| Financial assets at fair value through profit or loss             | \$ -                     | \$ 89                    |
| Financial assets at fair value through other comprehensive income | \$ 7,455                 | \$ 9,017                 |
| <u>Financial assets</u>   |                          |                          |
| Financial assets at amortised cost                                |                          |                          |
| Cash and cash equivalents   | \$ 759,330               | \$ 1,732,050             |
| Financial assets at amortised cost                                | 443,400                  | 1,411,600                |
| Accounts receivable   | 10,298                   | 4,200                    |
| Other receivables   | 54,150                   | 19,005                   |
| Refundable deposits (shown as 'other non-current asset')          | 35,373                   | 24,119                   |
|   | <u>\$ 1,302,551</u>      | <u>\$ 3,190,974</u>      |
| <u>Financial liabilities</u>                                      |                          |                          |
| Financial liabilities at amortised cost                           |                          |                          |
| Short-term borrowings   | \$ 50,353                | \$ 412                   |
| Notes payable   | -                        | 540                      |
| Accounts payable  | 985                      | 2,900                    |
| Other payables  | 116,870                  | 297,833                  |
| Long-term borrowings (including current portion)                  | 101,328                  | 82,311                   |
|   | <u>\$ 269,536</u>        | <u>\$ 383,996</u>        |
| Lease liabilities   | <u>\$ 363,996</u>        | <u>\$ 421,903</u>        |

## B. Financial risk management policies

- (a) The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk and price risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial position and financial performance.
- (b) Risk management is carried out by a central treasury department (Group treasury) under policies approved by the Board of Directors. Group treasury identifies, evaluates and hedges financial risks in close cooperation with the Company's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments, and investment of excess liquidity.

## C. Significant financial risks and degrees of financial risks

### (a) Market risk

#### Foreign exchange risk

- i. The Group operates internationally and is exposed to exchange rate risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to the USD and AUD. Exchange rate risk arises from future commercial transactions and recognised assets and liabilities.
- ii. Management has set up a policy to require group companies to manage their foreign exchange risk against their functional currency. The companies are required to hedge their entire foreign exchange risk exposure with the Group treasury.
- iii. The Group has certain investments in foreign operations, whose net assets are exposed to foreign currency translation risk.
- iv. The Group's businesses involve some non-functional currency operations (the Company's functional currency: NTD; the subsidiaries' functional currencies: USD and AUD). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

| December 31, 2025                             |   |                  |                      |                        |                             |  |
|---|---|------------------|----------------------|------------------------|-----------------------------|--|
|   |   |                  | Sensitivity Analysis |                        |                             |  |
| (Foreign currency:<br>functional<br>currency) | Foreign<br>currency<br>amount<br>(in thousands) | Exchange<br>rate | Book value<br>(NTD)  | Degree of<br>variation | Effect on<br>profit or loss | Effect on other<br>comprehensive<br>income |
| <u>Financial assets</u>                       |   |                  |                      |                        |                             |  |
| <u>Monetary items</u>                         |   |                  |                      |                        |                             |  |
| USD:NTD                                       | \$ 282  | 31.430           | \$ 8,863             | 1%                     | \$ 89                       | -  |
| AUD:NTD                                       | 1,069   | 21.010           | 22,460               | 1%                     | 225                         | -  |
| <u>Financial assets</u>                       |   |                  |                      |                        |                             |  |
| <u>Non-monetary<br/>items</u>                 |   |                  |                      |                        |                             |  |
| USD:NTD                                       | 2,871   | 31.430           | 90,240               | -                      | -                           | -  |
| AUD:NTD                                       | 1,784   | 21.010           | 37,490               | -                      | -                           | -  |
| <u>Financial liabilities</u>                  |   |                  |                      |                        |                             |  |
| <u>Monetary items</u>                         |   |                  |                      |                        |                             |  |
| USD:NTD                                       | 4,352   | 31.430           | 136,783              | 1%                     | 1,368                       | -  |
| December 31, 2024                             |   |                  |                      |                        |                             |  |
|   |   |                  | Sensitivity Analysis |                        |                             |  |
| (Foreign currency:<br>functional<br>currency) | Foreign<br>currency<br>amount<br>(in thousands) | Exchange<br>rate | Book value<br>(NTD)  | Degree of<br>variation | Effect on<br>profit or loss | Effect on other<br>comprehensive<br>income |
| <u>Financial assets</u>                       |   |                  |                      |                        |                             |  |
| <u>Monetary items</u>                         |   |                  |                      |                        |                             |  |
| USD:NTD                                       | \$ 87   | 32.785           | \$ 2,852             | 1%                     | \$ 29                       | -  |
| <u>Financial assets</u>                       |   |                  |                      |                        |                             |  |
| <u>Non-monetary<br/>items</u>                 |   |                  |                      |                        |                             |  |
| USD:NTD                                       | 2,694   | 32.785           | 88,334               | -                      | -                           | -  |
| AUD:NTD                                       | 908   | 20.390           | 18,520               | -                      | -                           | -  |
| <u>Financial liabilities</u>                  |   |                  |                      |                        |                             |  |
| <u>Monetary items</u>                         |   |                  |                      |                        |                             |  |
| USD:NTD                                       | 6,473   | 32.785           | 212,217              | 1%                     | 2,122                       | -  |
| EUR:NTD                                       | 147   | 34.140           | 5,019                | 1%                     | 50                          | -  |

v. The total exchange gain, including realised and unrealised, arising from significant foreign exchange variation on the monetary items held by the Group for the years ended December 31, 2025 and 2024, amounted to \$4,891 and \$25,442, respectively.

### Price risk

- i. The Group's equity securities, which are exposed to price risk, are the held financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Group.
- ii. The Group's investments in equity securities comprise shares and open-end funds issued by the domestic and foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 1% with all other variables held constant, post-tax profit for the years ended December 31, 2025 and 2024 would have increased/decreased by \$0 and \$1, respectively as a result of gains/losses on equity securities classified as at fair value through profit or loss. Other components of equity for the years ended December 31, 2025 and 2024 would have increased/decreased by \$75 and \$90, respectively, as a result of other comprehensive income on equity investment classified as equity investment at fair value through other comprehensive income.

### Cash flow and fair value interest rate risk

- i. The Group's interest rate risk arises from long-term and short-term borrowings. Borrowings issued at variable rates expose the Group to cash flow interest rate risk which is partially offset by cash and cash equivalents held at variable rates. The Group's borrowings were calculated by floating rate and stated at New Taiwan Dollars for the years ended December 31, 2025 and 2024.
- ii. At December 31, 2025 and 2024, if interest rates had been 1% higher or lower with all other variables held constant, post-tax profit for the years ended December 31, 2025 and 2024 would have been \$1,016 and \$300 lower or higher, respectively, mainly as a result of changes in interest expense on floating rate borrowings.

### (b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
- ii. The Group manages its credit risk taking into consideration the entire group's concern. For banks and financial institutions, only independently rated parties with stable credit rating are accepted. According to the Group's credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external

- ratings in accordance with limits set by the Board of Directors. The utilization of credit limits is regularly monitored.
- iii. Under IFRS 9, if the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
  - iv. The Group adopts the assumption under IFRS 9, that is, the default occurs when the contract payments are past due over 90 days.
  - v. The Group classifies customer's accounts receivable in accordance with customer types. The Group applies the simplified approach using loss rate methodology to estimate expected credit loss under the provision matrix basis.
  - vi. The following indicators are used to determine whether the credit impairment of debt instruments has occurred:
    - (i) It becomes probable that the issuer will enter bankruptcy or other financial reorganisation due to their financial difficulties;
    - (ii) The disappearance of an active market for that financial asset because of financial difficulties;
    - (iii) Default or delinquency in interest or principal repayments;
    - (iv) Adverse changes in national or regional economic conditions that are expected to cause a default.
  - vii. When estimating the allowance for uncollectible accounts for receivables, the Group incorporates forward-looking information in the adjustment of the loss rate, which is calculated based on historical data from specific periods and current information. As of December 31, 2025 and 2024, the expected loss rate of the Group's accounts receivable that are not past due is immaterial.
  - viii. For investments in debt instruments at amortised cost, the credit rating levels are presented below:

|                                    |  | December 31, 2025 |   |                         |              |
|------------------------------------|--|-------------------|---|-------------------------|--------------|
|                                    |  | Lifetime          |   |                         |              |
|                                    |  | 12 months         | Significant<br>increase in<br>credit risk | Impairment<br>of credit | Total        |
| Financial assets at amortised cost |  |                   |   |                         |              |
| Domestic bank                      |  | \$ 443,400        | \$ -                                      | \$ -                    | \$ 443,400   |
|                                    |  | December 31, 2024 |   |                         |              |
|                                    |  | Lifetime          |   |                         |              |
|                                    |  | 12 months         | Significant<br>increase in<br>credit risk | Impairment<br>of credit | Total        |
| Financial assets at amortised cost |  |                   |   |                         |              |
| Domestic bank                      |  | \$ 1,411,600      | \$ -                                      | \$ -                    | \$ 1,411,600 |

The debt instruments at amortised cost held by the Group are investment in certificates of deposit and the credit risk is well-managed without issues noted.

(c) Liquidity risk

- i. Cash flow forecasting is performed by Group treasury to monitor rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational and R&D needs. Such forecasting is in compliance with internal R&D project schedule targets.
- ii. Group treasury invests surplus cash in interest bearing current deposits, time deposits, and foreign currency deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient headroom as determined by the abovementioned forecasts.
- iii. The table below analyses the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date for non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows.

|   | December 31, 2025 |                |                |                |         |
|---|-------------------|----------------|----------------|----------------|---------|
|   | Less than         | Between 1      | Between 2      | Between 3      | Over    |
|   | 1 year            | and<br>2 years | and<br>3 years | and<br>5 years | 5 years |
| Non-derivative financial liabilities:               |                   |                |                |                |         |
| Short-term borrowings                               | \$ 50,353         | \$ -           | \$ -           | \$ -           | \$ -    |
| Accounts payable                                    | 985               | -              | -              | -              | -       |
| Other payables                                      | 116,870           | -              | -              | -              | -       |
| Long-term borrowings<br>(including current portion) | 72,998            | 29,574         | -              | -              | -       |
| Lease liabilities<br>(including current portion)    | 61,164            | 62,731         | 63,377         | 127,889        | 90,060  |

|   | December 31, 2024 |                |                |                |         |
|---|-------------------|----------------|----------------|----------------|---------|
|   | Less than         | Between 1      | Between 2      | Between 3      | Over    |
|   | 1 year            | and<br>2 years | and<br>3 years | and<br>5 years | 5 years |
| Non-derivative financial liabilities:               |                   |                |                |                |         |
| Short-term borrowings                               | \$ 416            | \$ -           | \$ -           | \$ -           | \$ -    |
| Notes payable                                       | 540               | -              | -              | -              | -       |
| Accounts payable                                    | 2,900             | -              | -              | -              | -       |
| Other payables                                      | 297,833           | -              | -              | -              | -       |
| Long-term borrowings<br>(including current portion) | 35,626            | 34,840         | 14,206         | -              | -       |
| Lease liabilities<br>(including current portion)    | 63,678            | 63,659         | 63,294         | 127,206        | 153,957 |

- iv. The Group does not expect the timing of occurrence of the cash flows estimated through the maturity date analysis will be significantly earlier, nor expect the actual cash flow amount will be significantly different.

### (3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3: Unobservable inputs for the asset or liability. The fair value of the Group's investment in financial assets at fair value through other comprehensive income and financial liabilities at fair value through profit or loss is included in Level 3.

- B. The book value of financial instruments not measured at fair value including cash and cash equivalents, financial assets at amortised cost, accounts receivable, other receivables, other financial assets (guarantee deposits paid), notes payable, accounts payable, and other payables is a reasonable approximation to their fair value; the interest rate on long-term and short-term borrowings (including the portion due within a year or one operating cycle) is close to the market interest rate, and therefore their book value is a reasonable basis for the estimation of their fair value.
- C. The related information on financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities is as follows:

|   | December 31, 2025 |             |                 |                 |
|---|-------------------|-------------|-----------------|-----------------|
|   | Level 1           | Level 2     | Level 3         | Total           |
| Assets  |                   |             |                 |                 |
| <u>Recurring fair value measurements</u>                          |                   |             |                 |                 |
| Financial assets at fair value through profit or loss             |                   |             |                 |                 |
| Foreign listed stocks   | \$ -              | \$ -        | \$ -            | \$ -            |
| Financial assets at fair value through other comprehensive income |                   |             |                 |                 |
| Equity securities   | -                 | -           | 7,455           | 7,455           |
|   | <u>\$ -</u>       | <u>\$ -</u> | <u>\$ 7,455</u> | <u>\$ 7,455</u> |
|   |                   |             |                 |                 |
|   | December 31, 2024 |             |                 |                 |
|   | Level 1           | Level 2     | Level 3         | Total           |
| Assets  |                   |             |                 |                 |
| <u>Recurring fair value measurements</u>                          |                   |             |                 |                 |
| Financial assets at fair value through profit or loss             |                   |             |                 |                 |
| Foreign listed stocks   | \$ 89             | \$ -        | \$ -            | \$ 89           |
| Financial assets at fair value through other comprehensive income |                   |             |                 |                 |
| Equity securities   | -                 | -           | 9,017           | 9,017           |
|   | <u>\$ 89</u>      | <u>\$ -</u> | <u>\$ 9,017</u> | <u>\$ 9,106</u> |

D. The methods and assumptions the Group used to measure fair value are as follows:

The instruments the Group used market quoted prices as their fair values (that is, Level 1) are listed below by characteristics:

|                     |                                       |
|---------------------|---------------------------------------|
| Market quoted price | <u>Listed stocks</u><br>Closing price |
|---------------------|---------------------------------------|

E. Financial segment is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price.

F. The following is the qualitative information on significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

|   | <u>Fair value at<br/>December<br/>31, 2025</u> | <u>Valuation<br/>technique</u>    | <u>Significant<br/>unobservable<br/>input</u> | <u>Range<br/>(median)</u>     | <u>Relationship<br/>of inputs to<br/>fair value</u>                               |
|---|--|-----------------------------------|---|-------------------------------|---|
| Non-derivative<br>equity instrument:<br>Unlisted shares | <u>\$ 7,455</u>                                | Market<br>comparable<br>companies | Price to book<br>ratio multiple               | 0.91~5.22<br>(1.50)           | The higher the multiple,<br>the higher the fair value                             |
|   |  |                                   | Discount for<br>lack of<br>marketability      | 16.89%~<br>32.35%<br>(22.36%) | The higher the discount<br>for lack of marketability,<br>the lower the fair value |
|   | <u>Fair value at<br/>December<br/>31, 2024</u> | <u>Valuation<br/>technique</u>    | <u>Significant<br/>unobservable<br/>input</u> | <u>Range<br/>(median)</u>     | <u>Relationship<br/>of inputs to<br/>fair value</u>                               |
| Non-derivative<br>equity instrument:<br>Unlisted shares | <u>\$ 9,017</u>                                | Market<br>comparable<br>companies | Price to book<br>ratio multiple               | 0.99~3.95<br>(1.62)           | The higher the multiple,<br>the higher the fair value                             |
|   |  |                                   | Discount for<br>lack of<br>marketability      | 10.69%~<br>33.60%<br>(21.32%) | The higher the discount<br>for lack of marketability,<br>the lower the fair value |

G. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. The following is the effect on profit or loss or on other comprehensive income from financial assets and liabilities categorised within Level 3 if the inputs used to valuation models have changed:

|                    |                                    |        | December 31, 2025            |                     |  |                     |
|--------------------|------------------------------------|--------|------------------------------|---------------------|--|---------------------|
|                    |                                    |        | Recognised in profit or loss |                     | Recognised in other comprehensive income |                     |
|                    | Input                              | Change | Favourable change            | Unfavourable change | Favourable change                        | Unfavourable change |
| Financial assets   |                                    |        |                              |                     |  |                     |
| Equity instruments | Price to book ratio multiple       | ±10%   | \$ -                         | \$ -                | \$ 741                                   | (\$ 741)            |
|                    | Discount for lack of marketability | ±10%   | \$ -                         | \$ -                | \$ 214                                   | (\$ 214)            |
|                    |                                    |        | December 31, 2024            |                     |  |                     |
|                    |                                    |        | Recognised in profit or loss |                     | Recognised in other comprehensive income |                     |
|                    | Input                              | Change | Favourable change            | Unfavourable change | Favourable change                        | Unfavourable change |
| Financial assets   |                                    |        |                              |                     |  |                     |
| Equity instruments | Price to book ratio multiple       | ±10%   | \$ -                         | \$ -                | \$ 901                                   | (\$ 901)            |
|                    | Discount for lack of marketability | ±10%   | \$ -                         | \$ -                | \$ 245                                   | (\$ 245)            |

H. The following chart is the movement of Level 3 for the years ended December 31, 2025 and 2024:

|   | Year ended December 31, 2025 |                   |          |
|---|------------------------------|-------------------|----------|
|   | Equity securities            | Hybrid instrument | Total    |
| Opening net book amount                       | \$ 9,017                     | \$ -              | \$ 9,017 |
| Loss recognised in other comprehensive income | ( 1,562)                     | -                 | ( 1,562) |
| Closing net book amount                       | \$ 7,455                     | \$ -              | \$ 7,455 |

|   | Year ended December 31, 2024 |                          |                 |
|---|------------------------------|--------------------------|-----------------|
|   | <u>Equity securities</u>     | <u>Hybrid instrument</u> | <u>Total</u>    |
| Opening net book amount                       | \$ 10,621                    | \$ 46,057                | \$ 56,678       |
| Loss recognised in other comprehensive income | ( 1,604)                     | -                        | ( 1,604)        |
| Disposals                                     | -                            | ( 48,623)                | ( 48,623)       |
| Effect of exchange rate changes               | -                            | 2,566                    | 2,566           |
| Closing net book amount                       | <u>\$ 9,017</u>              | <u>\$ -</u>              | <u>\$ 9,017</u> |

### 13. SUPPLEMENTARY DISCLOSURES

#### (1) Significant transactions information

- A. Loans to others: Refer to table 1.
- B. Provision of endorsements and guarantees to others: None.
- C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): None.
- D. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: None
- E. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: None.
- F. Significant inter-company transactions during the reporting period: Refer to table 2.

#### (2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 3.

#### (3) Information on investments in Mainland China

- A. Basic information: None.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: None.

### 14. SEGMENT INFORMATION

#### (1) General information

Management has determined the reportable operating segments based on the reports reviewed by the chief operating decision-maker that are used to make strategic decisions.

The Group has three reportable segments, which are anti-cancer new drug segment, botulinum toxin new drug segment and CDMO segment. The segments are identified in the functional perspective such as the territory of the research and development of new drugs and CDMO (Contract Development and Manufacturing Organization).

## (2) Measurement of segment information

All operating segments of the Group apply the same accounting policies.

## (3) Segment information

The segment income or loss after tax reported to the chief operating decision-maker is measured in a manner consistent with revenues and expenses in the statement of comprehensive income. For the years ended December 31, 2025 and 2024, the segment information provided to the chief operating decision-maker for the reportable segments is as follows:

|                                     | Anti-cancer<br>new drug | Botulinum<br>toxin<br>new drug | CDMO                | Reconciliation<br>and<br>elimination | Total                 |
|-------------------------------------|-------------------------|--------------------------------|---------------------|--------------------------------------|-----------------------|
| <u>Year ended December 31, 2025</u> |                         |                                |                     |                                      |                       |
| Revenue from external customers     | \$ 8,568                | \$ -                           | \$ 50,007           | \$ -                                 | \$ 58,575             |
| Inter-segment revenue               | -                       | -                              | 19,267              | (19,267)                             | -                     |
| Total segment revenue               | <u>\$ 8,568</u>         | <u>\$ -</u>                    | <u>\$ 69,274</u>    | <u>(\$ 19,267)</u>                   | <u>\$ 58,575</u>      |
| Segment loss                        | <u>(\$ 1,572,075)</u>   | <u>(\$ 325,963)</u>            | <u>(\$ 163,501)</u> | <u>(\$ 195,215)</u>                  | <u>(\$ 2,256,754)</u> |
| Segment loss, including:            |                         |                                |                     |                                      |                       |
| Depreciation                        | \$ 71,907               | \$ 72,631                      | \$ 62,245           | \$ -                                 | \$ 206,783            |
| Amortisation                        | 14,839                  | 42,059                         | 4,804               | (41,323)                             | 20,379                |
| Finance costs                       | 5,185                   | 1,724                          | 6,239               | (15)                                 | 13,133                |
| Interest income                     | 19,954                  | 9,466                          | 374                 | -                                    | 29,794                |
| <br>                                |                         |                                |                     |                                      |                       |
|                                     | Anti-cancer<br>new drug | Botulinum<br>toxin<br>new drug | CDMO                | Reconciliation<br>and<br>elimination | Total                 |
| <u>Year ended December 31, 2024</u> |                         |                                |                     |                                      |                       |
| Revenue from external customers     | \$ 1,883                | \$ -                           | \$ 60,795           | \$ -                                 | \$ 62,678             |
| Inter-segment revenue               | 1,490                   | -                              | 26,612              | (28,102)                             | -                     |
| Total segment revenue               | <u>\$ 3,373</u>         | <u>\$ -</u>                    | <u>\$ 87,407</u>    | <u>(\$ 28,102)</u>                   | <u>\$ 62,678</u>      |
| Segment loss                        | <u>(\$ 1,829,948)</u>   | <u>(\$ 274,308)</u>            | <u>(\$ 148,488)</u> | <u>(\$ 239,902)</u>                  | <u>(\$ 2,492,646)</u> |
| Segment loss, including:            |                         |                                |                     |                                      |                       |
| Depreciation                        | \$ 59,585               | \$ 69,979                      | \$ 73,924           | (\$ 85)                              | \$ 203,403            |
| Amortisation                        | 15,369                  | 42,051                         | 2,747               | (41,316)                             | 18,851                |
| Finance costs                       | 6,335                   | 2,004                          | 2,312               | -                                    | 10,651                |
| Interest income                     | 27,572                  | 11,845                         | 654                 | -                                    | 40,071                |

(4) Geographical information

Geographical information for the years ended December 31, 2025 and 2024 is as follows:

|        | Years ended December 31, |                     |                  |                     |
|--------|--------------------------|---------------------|------------------|---------------------|
|        | 2025                     |                     | 2024             |                     |
|        | Revenue                  | Non-current assets  | Revenue          | Non-current assets  |
| Taiwan | \$ 42,157                | \$ 1,041,724        | \$ 60,679        | \$ 1,224,213        |
| Others | 16,418                   | 342                 | 1,999            | 5,727               |
|        | <u>\$ 58,575</u>         | <u>\$ 1,042,066</u> | <u>\$ 62,678</u> | <u>\$ 1,229,940</u> |

Non-current assets include property, plant and equipment, right-of-use assets, intangible assets and other non-current assets (excluding guarantee deposits paid), and are classified based on their geographic location.

(5) Significant customer information

In 2025 and 2024, the Group's revenues to a single customer accounting for more than 10% of consolidated operating income is as follows:

|           | 2025      |                  | 2024     |                  |
|-----------|-----------|------------------|----------|------------------|
|           | Revenue   | Division         | Revenue  | Division         |
| Company J | \$ 14,156 | CDMO             | \$ 1,714 | CDMO             |
| Company C | 10,332    | CDMO             | 1,999    | CDMO             |
| Company G | 7,753     | CDMO             | 13,120   | CDMO             |
| Company H | 6,573     | CDMO             | 5,145    | CDMO             |
| Company K | 6,086     | Anti-cancer drug | -        | Anti-cancer drug |
| Company A | 1,736     | CDMO             | 22,031   | CDMO             |

OBI Pharma, Inc. and Subsidiaries

Loans to others

Year ended December 31, 2025

Table 1

Expressed in thousands of NTD

(Except as otherwise indicated)

| No. | Creditor         | Borrower                  | Is a related party | General ledger account            | Maximum outstanding balance during the year ended December 31, 2025 | Balance at December 31, 2025 | Actual amount drawn down | Interest rate | Nature of loan (Note 2) | Amount of transactions with the borrower | Reason for short-term financing | Allowance for doubtful accounts | Collateral |       | Limit on loans granted to a single party | Ceiling on total loans granted | Footnote |
|-----|------------------|---------------------------|--------------------|-----------------------------------|---|------------------------------|--------------------------|---------------|-------------------------|--|---------------------------------|---------------------------------|------------|-------|--|--------------------------------|----------|
|     |                  |                           |                    |                                   |   |                              |                          |               |                         |  |                                 |                                 | Item       | Value |  |                                |          |
| 0   | OBI Pharma, Inc. | Amaran Biotechnology Inc. | Y                  | Other receivables - related party | \$ 60,000   | \$ 60,000                    | \$ 30,000                | 2.31%         | 2                       | \$ -                                     | Working capital                 | \$ -                            | -          | \$ -  | \$ 188,856                               | \$ 755,422                     | Note 1   |

Note 1: Ceiling on total loans from a subsidiary to others is 40% of the subsidiary's net assets and limit on loans from a subsidiary to a single party is 10% of the subsidiary's net assets.

Note 2: The nature of the loan is as follows:

- (1) Business transaction: 1
- (2) Short-term financing: 2

OBI Pharma, Inc. and Subsidiaries  
Significant inter-company transactions during the reporting period  
Year ended December 31, 2025

Table 2

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Number<br>(Note 1) | Company name              | Counterparty     | Relationship | Transaction   |           |                   | Percentage of consolidated<br>total operating revenues or<br>total assets (Note 3) |
|--------------------|---------------------------|------------------|--------------|---|-----------|-------------------|--|
|                    |                           |                  |              | General ledger account                                      | Amount    | Transaction terms |  |
| 1                  | OBI Pharma USA, Inc.      | OBI Pharma, Inc. | 2            | Accounts receivable   | \$ 81,843 | (Note 4)          | 2.39   |
| 1                  | "                         | "                | 2            | Service revenue   | 301,024   | "                 | 513.91   |
| 2                  | Amaran Biotechnology Inc. | "                | 2            | CMO revenue and calibration<br>and analysis service revenue | 19,216    | "                 | 32.81  |
| 2                  | "                         | "                | 2            | Other payables  | 30,015    | "                 | 0.88   |

Note 1: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

- (1) Parent company is '0'.
- (2) The subsidiaries are numbered in order starting from '1'.

Note 2: Relationship between transaction company and counterparty is classified into the following three categories:

- (1) Parent company to subsidiary.
- (2) Subsidiary to parent company.
- (3) Subsidiary to subsidiary.

Note 3: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for consolidated income statement accounts.

Note 4: The transaction terms are based on the mutual agreement.

Note 5: Only those inter-company transactions exceeding \$10,000 are disclosed, with the transactions from the counterparty undisclosed.

OBI Pharma, Inc. and Subsidiaries  
Information on investees  
Year ended December 31, 2025

Table 3

Expressed in thousands of NTD  
(Except as otherwise indicated)

| Investor         | Investee                      | Location  | Main business activities  | Initial investment amount             |                                       | Shares held as at December 31, 2025 |                  |            | Net income (loss)<br>of the investee for the<br>year ended December<br>31, 2025 | Investment income<br>(loss) recognised by<br>the Company for the<br>year ended December<br>31, 2025 | Footnote |
|------------------|-------------------------------|-----------|---|---------------------------------------|---------------------------------------|-------------------------------------|------------------|------------|---|---|----------|
|                  |                               |           |   | Balance as at<br>December 31,<br>2025 | Balance as at<br>December 31,<br>2024 | Number of shares                    | Ownership<br>(%) | Book value |   |   |          |
| OBI Pharma, Inc. | AP Biosciences, Inc.          | Taiwan    | Research and development of biotechnology   | \$ 558,276                            | \$ 558,276                            | 23,223,000                          | 27.21            | \$ 739,886 | (\$ 444,767)  | (\$ 201,992)  |          |
| "                | Amaran Biotechnology Inc.     | Taiwan    | Manufacture and wholesale of western pharmaceuticals as well as research and development of biotechnology | 676,096                               | 676,096                               | 64,915,252                          | 70.68            | 180,766    | ( 163,501)  | ( 109,320)  | Note 2   |
| "                | Obigen Pharma, Inc.           | Taiwan    | Research and development of biotechnology   | 1,150,271                             | 1,195,000                             | 53,001,500                          | 49.57            | 44,880     | ( 325,963)  | ( 167,372)  | "        |
| "                | OBI Pharma USA, Inc.          | USA       | Research and development of biotechnology   | 84,861                                | 84,861                                | 2,701,000                           | 100.00           | 90,240     | 3,448   | 3,448   | "        |
| "                | OBI Pharma Australia Pty Ltd. | Australia | Research and development of biotechnology   | 357,170                               | 304,645                               | 17,000,000                          | 100.00           | 37,490     | ( 32,621)   | ( 32,621)   | "        |

Note 1: The accounts of the Company are maintained in New Taiwan dollars. Income statement accounts denominated in foreign currencies are translated into New Taiwan dollars at the weighted average exchange rates and balance sheet accounts at spot exchange rates prevailing at the balance sheet date.

Note 2: Inter-company transactions between companies within the Group are eliminated.